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Abstract 
Equine athletes and companion horses are commonly treated with glucocorticoids such 
as dexamethasone. Care of sick or injured animals is vital for the animal welfare. To 
protect the integrity of equine sport, legal therapeutic substances are regulated during 
competition. The overall aim of this thesis was to provide quantitative information of 
dexamethasone exposure and response in Standardbreds and to relate this information 
to medication and anti-doping methodology.  
Dexamethasone-21-isonicotinate suspension administered intramuscularly and 
dexamethasone sodium phosphate solution administered both intravenously and intra- 
articularly were used in experiments. Dexamethasone was quantified in plasma, urine 
and synovial fluid by means of UHPLC-MS/MS. Cortisol response, IL-1β response, 
joint circumference response, local skin temperature response and lameness response 
were used as biomarkers. Dexamethasone plasma- and synovial fluid concentration-
time courses were characterised by means of compartment modelling. The response-
time courses were described by fitting a turnover model with an inhibitory function to 
experimental biomarker response data.  
Dexamethasone exposure was described in plasma and synovial fluid. In the 
Standardbreds studied, median dexamethasone plasma clearance was 0.51 L∙h-1∙kg-1 
and median volume of distribution (at steady state) was 1.58 L∙kg-1. The median half-
life in plasma and synovial fluid was 2.4 h and 1.3 h, respectively. After intramuscular 
administration of dexamethasone-21-isonicotinate, mean terminal half-life was 39 h 
due to slow release into plasma from the injection site. The dexamethasone 
concentration was 4- to 15-fold higher in urine than in plasma. A circadian cortisol 
baseline was described using a cosine function and cortisol response was characterised. 
Median potency value and for cortisol response in plasma was 0.039 ng∙mL-1 and the 
efficacy value was 0.92. Dexamethasone inhibited lameness and synovial fluid IL-1β 
release at doses lower than the approved. The median calculated synovial fluid 
concentration that suppressed lameness response by 50 % was 17 ng∙mL-1. The tentative 
potency value for IL-1β response was 19 ng∙mL-1.  
The information provided in this thesis can be used to improve future medication 
protocols and anti-doping controls which could improve animal welfare.  
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integrative pharmacology, quantitative pharmacology, corticosteroids, glucocorticoids 
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Dedication 
To Karin, Alice and Edvin. 
Future generations will judge us not by what we say, but what we do. 
Ellen Johnson Sirleaf 
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1 Introduction 
1.1 Glucocorticoids in a historic perspective  
In 1950, Edward Calvin Kendall, Tadeus Reichstein and Philip Showalter 
Hench were awarded the Nobel Prize for Physiology and Medicine “for their 
discoveries relating to the hormones of the adrenal cortex, their structure and 
biological effects” (Nobel Media, 2014). The main group of hormones 
originating from the adrenal cortex are the corticosteroids. They can be further 
divided into the subgroups mineralocorticoids and glucocorticoids. Due to their 
effective and potent anti-inflammatory and immune-suppressive properties, 
glucocorticoids rapidly became essential in treatment of rheumatoid arthritis in 
humans (Kendall, 1951a, b, 1959).  
Glucocorticoids such as dexamethasone are now frequently used in both 
human and veterinary medicine. Several pharmaceutical preparations and 
routes of administration are registered for use in horses (Medical Products 
Agency, 2010, 2015). In the 1960s and 1970s, the clinical response to gluco-
corticoids administered intraarticularly (ia) to horses with joint disease, e.g. 
osteoarthritis was investigated (Trussel, 1965; Van Pelt & Riley, 1967; 
Houdeshell, 1969, 1970; Van Pelt et al., 1970; Van Pelt et al., 1971; Vernimb 
et al., 1977). In these early studies, different substances and pharmaceutical 
preparations were used. Based on the results, it was concluded that horses 
responded satisfactorily to the treatment. The onset of response was reported 
within two days, the clinical response was positive in up to more than 90 % of 
the treated horses and the outcome of treatment was in general terms referred 
to as e.g. “good” or “excellent”. More recent studies have also reported the 
response to glucocorticoid treatment in horses to be 27-88 % successful 
(Labens et al., 2007; Kay et al., 2008; Brommer et al., 2012; de Grauw et al., 
2016). Those studies include both prospective and retrospective studies on joint 
disease as well as experimental models of joint inflammation. The response to 
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glucocorticoids of inflammatory airway disease, e.g. recurrent airway 
obstruction, has also been extensively studied. In the literature, there is strong 
evidence of a reduction in both clinical signs and biomarker response, 
indicating improved airway function, after both topical and systemic 
administration of glucocorticoids (Ammann et al., 1998; Robinson et al., 2002; 
Picandet et al., 2003; Robinson et al., 2003; Cornelisse et al., 2004; Couetil et 
al., 2006; DeLuca et al., 2008; Leclere et al., 2010). A response to 
glucocorticoid treatment of other inflammatory conditions in horses has also 
been described (Frauenfelder et al., 1982; McCue et al., 2003; Christoffersen et 
al., 2012). 
1.2 Pharmacokinetics and pharmacodynamics 
1.2.1 General concepts 
One description of pharmacology is that it is the study of how drugs interact 
with the body. Two disciplines within pharmacology are pharmacokinetics 
(PK) and pharmacodynamics (PD). One prerequisite for any drug response is 
that the drug must be available at the site where it will exert its action. If the 
drug is designed for topical administration, it may be distributed locally to this 
(local) site. If the site of action is out of reach the drug must be transported to 
the target tissue by the blood stream, regardless what route of administration 
that was used. If the drug not is injected into the blood it must be absorbed 
before it is distributed by the circulation to the site where it exerts its action. 
The drug most commonly also must be transported to the site where it is 
removed (eliminated) from the body or metabolised. Hence, PK is the study of 
absorption, distribution, metabolism and elimination of a drug. In other words, 
PK can be described as what the body does to the drug (Benet & Zia-
Amirhosseini, 1995). 
One description that has been used for PD is what the drug does to the body 
(Holford & Sheiner, 1982; Derendorf & Meibohm, 1999). Most drugs act by 
interaction with a biological target to produce a response. This target might be 
an enzyme, a receptor located on the cell surface or within the cell, a carrier 
(transport) molecule, an ion channel etc. The resulting PD can be reported in 
qualitative and quantitative terms. Qualitative terms describe how a biomarker 
or clinical response changes using a categorical outcome (e.g. treatment was 
poor, fair, good, etc.) or relative to a baseline (e.g. biomarker value was 60 % 
lower after treatment). Quantitative terms for PD describe the change in 
biomarker response numerically, i.e. PD (model) parameter estimates are 
reported. Examples of PD-parameters are potency values (EC50/IC50-value), 
which is the concentration that generates 50 % of maximum response, efficacy 
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values (Emax and Imax) and information about the concentration-response 
relationship (sigmoidicity factor, n). The ideal potency value would be the free 
concentration at the target site. This concentration is often not measured for 
practical reasons. Rather, the blood (e.g. plasma or serum) or synovial fluid 
drug concentration is often used as a surrogate concentration.  
Three relationships should be considered to include in PK/PD analysis: 
Drug concentration versus time, drug response versus time and drug response 
versus drug concentration. The use of PK/PD analyses and integration of these 
relationships simplifies interpretation of a data set when the concentration-time 
course is different from the response-time course e.g. due to a delay because of 
physiological processes. For example if the response to a drug is dependent on 
altering gene expression in order to influence the release of a protein. 
Pharmacodynamic modelling by means of e.g. effect compartment models and 
turnover models relate drug concentration to the response and are examples of 
integration of the concentration-time and response-time courses (Segre, 1968; 
Sheiner et al., 1979; Dayneka et al., 1993; Levy, 1994). The use of quantitative 
methods also makes it possible to build models to simulate concentration-
response relationships or time courses beyond what has been studied in the 
experiment. This reduces the numbers of animals and is favourable from a 
scientific and economic perspective. Attempts to quantify the response to 
glucocorticoid exposure in humans and rodents by means of biomarkers have 
successfully been done by Jusko and co-workers, affiliated to University at 
Buffalo, the State University of New York (Dayneka et al., 1993; Lew & 
Jusko, 1993; Jusko, 1995; Chakraborty et al., 1999; Krzyzanski et al., 2000; 
Chakraborty et al., 2005; Jin & Jusko, 2009) 
1.2.2 Pharmacokinetics of dexamethasone in the horse 
The plasma dexamethasone exposure has been described and some studies also 
provide PK information on different pharmaceutical preparations in both 
Saddlebreds and Thoroughbreds (Toutain et al., 1984; Cunningham et al., 
1996; Soma et al., 2005; Authie et al., 2010; Grady et al., 2010; Soma et al., 
2013). Consequently, quantitative information and reported values of PK 
parameters e.g. bioavailability (F), clearance (Cl), volume (V) and rate 
constants for absorption and elimination are available. However, plasma 
dexamethasone exposure of after intramuscular (im) administration of dexa-
methasone-21-isonicotinate slow release suspension has not been published. In 
addition, there is sparse information on plasma dexamethasone disposition in 
Standardbreds. 
For synovial fluid, there is no information available on the exposure of 
dexamethasone following ia administration.   
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1.2.3 Pharmacodynamics of dexamethasone in the horse 
The response to dexamethasone has been described in qualitative terms using 
both clinical signs and other biomarkers of anti-inflammatory, metabolic, 
haematological and endocrine response (Osbaldiston & Johnson, 1972; Toutain 
et al., 1984; Lane et al., 1990; Salles-Gomes et al., 2003; Cornelisse et al., 
2004; Soma et al., 2005; Cartmill et al., 2006; Abraham et al., 2009; Grady et 
al., 2010; Abraham et al., 2011; Soma et al., 2013). However, none of those 
studies has presented convincing quantitative information based on PK/PD 
modelling. On the contrary, plasma glucocorticoid concentration has been 
suggested to be less important for the response than intracellular dexa-
methasone concentrations and therefore irrelevant (Lees et al., 1990; Grady et 
al., 2010). In contrast, in human medicine a clear plasma glucocorticoid 
concentration-response relationship has been described (Kong et al., 1989; 
Lew & Jusko, 1993; Rohatagi et al., 1996a; Rohatagi et al., 1996b; Mager et 
al., 2003). Moreover, it has been found that increasing the glucocorticoid doses 
during inhalation therapy also increases the cortisol response (i.e. decreasing 
the cortisol plasma concentration) in horses (Rush et al., 1999). 
Cortisol (endogenous hydrocortisone) response has frequently been used as 
a biomarker of response to dexamethasone exposure (Eiler et al., 1979; Slone 
et al., 1983; Toutain et al., 1984; MacHarg et al., 1985; Soma et al., 2005; 
Abraham et al., 2009; Grady et al., 2010; Soma et al., 2013). However, the 
only quantitative information presented in those studies is a proposed 
dexamethasone threshold concentration in plasma (0.19 ng∙mL-1) “switching 
off” cortisol production (Soma et al., 2005). In contrast, the glucocorticoid 
beclomethasone suppress cortisol response dose dependently (Rush et al., 
1999). However, despite the similarity in changes over time of cortisol 
response and pleural pressure response in horses with airway obstruction 
treated with dexamethasone, there is no evidence that cortisol response is a 
suitable marker for the anti-inflammatory response to dexamethasone 
(Cornelisse et al., 2004; Soma et al., 2005). 
1.3 Doping and medication control of equine athletes 
1.3.1 Background, rules and legislations 
Many substances may alter the performance of equine athletes and endanger 
animal welfare and fair competition and put the integrity of the sport at risk. 
Therefore, some substances (e.g. anabolic steroids) are banned from use in 
sport-horses by many regulatory organisations, e.g. members of Fédération 
Equestre Internationale (FEI) and the International Federation of Horseracing 
Authorities (IFHA) (FEI, 2017a; IFHA, 2017a). Finding of a banned substance 
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and/or its metabolite or prodrug in plasma or urine samples from a sport-horse 
is considered to be conclusive evidence for doping, so called zero tolerance 
policy. However, for animal welfare reasons, sick or injured animal must be 
given proper care, which includes medication with legitimate therapeutic 
substances e.g. dexamethasone. These legitimate therapeutic substances could 
also alter performance of the horse, so their use temporarily puts horses out of 
competition. These rules are applied in many jurisdictions, e.g. members of FEI 
and IFHA (FEI, 2017a; IFHA, 2017a). In Sweden, it is currently also a legal 
requirement that horses are kept out of competition when performance is 
altered by legitimate drugs (SJVFS 2013:43). Improvements in analytical 
techniques have made it possible to detect legal substances for an extended 
time post-administration and after environmental contamination, even at 
concentrations considered non-efficacious, so a zero tolerance policy is not an 
option for these drugs (Barragry, 2006). It is important that trainers/owners can 
trust that appropriate use of legitimate drugs will never lead to doping 
accusations. The use of quantitative PK and PD can be useful in establishing 
screening limits, detection times and withdrawal times which are all tools 
guaranteeing that correct use of legitimate drugs will not be considered as 
doping. Thus, the control of legitimate medication is upheld simultaneously as 
it allows veterinarians to apply good veterinary practice when treating sport-
horses.   
1.3.2 Screening limits 
A screening limit (SL), also called screening sensitivity limit, is a concentration 
in a biological fluid (usually plasma or urine) that is considered irrelevant 
(Toutain, 2010b). The SL is decided by the regulatory authorities in the sport 
and is commonly confidential. However, one aim of the European Horserace 
Scientific and Liaison Committee (EHSLC) is to harmonise SL values between 
its members’ jurisdictions. One commonly used method to decide a SL is a 
PK/PD approach often referred to as the Toutain model (Toutain & Lassourd, 
2002).  In brief, the approach involves calculating an effective plasma concen-
tration (EPC) by means of the standard dose (e.g. as indicated in the marketing 
authorisation for the drug) and the clearance value (taken from the literature). 
A safety (uncertainty) factor (SF) is then applied to account for the variation in 
pharmacological parameters (e.g. clearance and drug potency values) between 
individuals and an irrelevant plasma concentration (IPC) is decided. The SF 
used must ensure that the IPC is truly irrelevant, i.e. the drug does not have any 
effect that alters the performance of the horse at this concentration. If the 
steady state ratio between plasma and urine is known, the Toutain model can 
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also be used to calculate effective and irrelevant urine concentrations (EUC and 
IUC). 
1.3.3 Detection times 
Both EHSLC and FEI have listed detection times (DT) for several therapeutic 
drugs (EHSLC, 2015; FEI, 2017b). A DT is based on an exposure study and 
represents the longest time a drug can be detected in plasma or urine after 
administration, i.e. the time point for the first negative sample, defined as when 
the sample concentration in all horses in the study is below a proposed 
screening sensitivity limit. The establishment of a DT follows a strict protocol. 
The dose and the route of administration must be as recommended by the 
manufacturer or represent most common clinical practice and the analytical 
procedure must be validated. The study uses healthy horses under scientific 
conditions which may not be representative to the conditions of a sport horse. 
Therefore, even though DT values are published by racing authorities, they 
should not be regarded as guaranteeing a negative doping test on race day. 
They only serve as one tool for the stakeholders, trainers and veterinarians to 
estimate a ‘safe’ time from treatment to competition.  
1.3.4 Withdrawal times 
A withdrawal time (WT) is the time from administration of a drug until the 
concentration in a biological fluid is below a proposed screening sensitivity 
limit in the entire population of horses (EHSLC, 2012). To minimise the risk of 
a positive sample on race day, WT must be longer than DT, which reflects the 
precise conditions of the exposure study. To compensate for possible variations 
in disposition of a drug within a population of horses (e.g. age, breed, sex, drug 
accumulation etc.) an adequate safety margin must be added to the DT. If any 
condition (dosing, pharmaceutical preparation, administrative route etc.) is 
different from the study that established the DT, this must also be taken into 
account. It has been proposed that variation in intrinsic factors (clearance, 
volume of distribution plasma-urine ratio etc.) is more important than variation 
in extrinsic factors (dose, route of administration etc.) (Toutain, 2010a). 
However, both intrinsic and extrinsic factors contribute to how the drug is 
dispositioned in body fluids. For drugs showing low variability in PK parameter 
estimates e.g. clearance, an increase of approximately 40% in DT might be a 
suitable WT, encompassing 90 % of the horse population, whilst doubling of 
the DT might be necessary with high variability in PK parameters (Toutain, 
2010b; Toutain, 2010a; Tobin et al., 2013) 
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1.3.5 Science as a screening limit additive for dexamethasone 
There are some prerequisites for establishment of screening limits in plasma 
(and urine). Three basic assumptions according to Toutain & Lassourd (2002) 
are: i) The drug-induced responses are reversibly driven by the plasma 
concentration and a relationship between overall drug exposure and drug 
response exists ii) the dosing regimens currently used (under authority 
approval or in clinical practice) are appropriate, the doses are efficacious and 
does not greatly exceed the dose that gives 50 % of the maximum response, 
and iii) the drug disposition is linear within the range of plasma concentrations 
and plasma clearance is a parameter relating the dose to the plasma conc-
entration.  
The disposition of dexamethasone in plasma has been investigated in horses 
and there is consistent evidence of linear kinetics within the concentration 
ranges studied (Toutain et al., 1984; Cunningham et al., 1996; Soma et al., 
2005; Grady et al., 2010; Soma et al., 2013). As already mentioned there are 
only very sparse quantitative PD data reported in the literature. Quantitative 
reports on plasma dexamethasone concentration-response time courses would 
improve the scientific evidence and be beneficial for anti-doping control of 
therapeutic substances in horse racing and equestrian sport.  
1.4  Problem formulation 
Dexamethasone plasma concentration has been proposed irrelevant for the 
response. The focus in this thesis has been to apply quantitative methods (e.g. 
nonlinear regression modelling) to experimental data in order to obtain 
quantitative information to use in the design of future experiments, for dose-
calculations and in the control of therapeutic substances within the anti-doping 
control of equine athletes. This was done by means of assessing i) the 
dexamethasone exposure in plasma, urine and synovial fluid and ii) the bio-
marker response. Then i) and ii) was combined.  
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2 Aims 
The overall aim of this thesis was to provide information about dexamethasone 
exposure and response in Standardbreds by means of quantitative methods. 
Specific aims were to: 
 
? Determine the dexamethasone exposure in plasma, urine and synovial fluid 
after intramuscular, intravenous or intraarticular administration of dexa-
methasone-21-isonicotinate or dexamethasone sodium phosphate.  
? Determine the relationships between i) dexamethasone plasma concen-
tration and cortisol response and ii) the dexamethasone synovial fluid 
concentration and interleukine-1β response and lameness response in a 
lipopolysaccharide-challenged joint 
? Determine clinical endpoint response to dexamethasone treatment of the 
LPS-challenged joint 
? Position the quantitative information in an anti-doping perspective 
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3 Overview and progression of studies 
The goal of this thesis was to investigate the exposure and response to dexa-
methasone. Overview and progression of studies are summarised in Table 1.   
Table 1. Thesis overview including problem formulation, hypothesis, key findings, conclusions 
and future perspectives 
 Paper I Paper II Paper III Paper IV 
Problem Drug exposure and 
response in horses 
Drug exposure and 
response 
Baseline variability 
Drug exposure 
IL-1β response 
Cortisol response 
Clinical endpoint 
response 
Hypothesis Concentration-
response relation-
ship possible 
Improve model fitting Concentration-
response relation-
ship 
Clinical endpoint vs 
IL-1β response 
Concentration-
response relationship 
Key 
findings 
Concentration-time 
course 
Response-time 
course 
Concentration-
response hysteresis 
Concentration-time 
course 
Response-time course 
Baseline variability 
 
Concentration-
time courses 
Concentration-IL-
1β response 
Challenge 
variability 
 
Challenge variability 
Concentration-
lameness response 
relationship 
Conclusions Response is related 
to concentration 
Exposure: anti-
doping perspective 
The model mimicked 
data well 
Parameter consistency 
Improved test design 
The model 
predicted drug 
exposure 
The model 
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4 Material and Methods 
4.1 Animals and ethics 
Standardbred horses were used in all experiments. In Paper I, a study pop-
ulation consisting of six geldings aged 3-16 years and weighing 420-545 kg 
was used. In Paper II, a study population consisting of four mares and two 
geldings aged 6-20 years and weighing 430-584 kg was used. In Papers III and 
IV, a study population of three mares and three geldings aged 3-9 years and 
weighing 429-550 kg was used.  
During experimental periods, the horses were kept in individual boxes and 
fed hay. Water was available ad libitum. In Paper I, the horses were also fed 
oats, while in Papers III and IV the horses were also fed concentrate 
(Champion komplett, Felleskjøpet,Lillestrøm, Norway). In Papers I and II the 
horses were kept in their home environment and allowed on pasture or in 
paddocks during daytime. In Paper III and IV the horses were brought into an 
animal hospital three days prior to the start of the each experimental period and 
kept in individual boxes during experimental periods. Between experimental 
periods the horses were kept on pasture. The horses were not exercised in any 
study. 
The experiments described in Papers I and II were approved by Ethics 
Committee for Animal Experiments, Uppsala, Sweden (C232/8, C333/11). The 
experiment described in Papers III and IV was approved by the Norwegian 
Animal Research Authority (Forsøksdyrutvalget 2013/61618-1). 
4.2 Experimental design, drug administration and sampling 
protocol 
In Paper I dexamethasone-21-isonicotinate (Vorenvet®Vet 1 mg∙mL-1 Boeh-
ringer Ingelheim Vetmedica, Malmö, Sweden) was administered as a single im 
dose of 0.03 mg∙kg-1 in the neck. Blood samples were drawn at hours -120, -96, 
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-72, -48, -24, 0 (pre-dose), 1, 2, 4, 8, 12 and 24. Thereafter, blood was sampled 
at 24 hours interval up to 30 days. Urine was sampled before drug admini-
stration, twice within 24-hours post drug administration and thereafter once 
daily up to 30 days.  
In Papers II-IV dexamethasone 21-phosphate disodium salt (DSP, Dexa-
dreson 2 mg∙mL-1, Intervet AB, Stockholm, Sweden) and 0.9 % saline 
(Natriumklorid Fresenius Kabi, Fresenius Kabi AB, Uppsala, Sweden) were 
used. 
In Paper II the horses were divided into pairs and assigned to a randomised 
crossover design experiment including four treatments. Each treatment started 
with an intravenous (iv) bolus dose immediately followed by 3 h of constant-
rate infusion. The dose levels were (bolus + infusion) 0.1 + 0.07 μg∙kg-1, 1 + 
0.7 μg∙kg-1 and 10 + 7 μg∙kg-1 dexamethasone. For the control 0.9 % saline was 
used. The concentrations of the dosing solutions were adjusted to give an 
infusion volume flow rate of 0.2 mL∙kg∙h-1. Infusions were given using a 
volumetric infusion pump (Colleague, Baxter Healthcare Corporation, 
Deerfield, Illinois, USA). All dosing solutions were prepared within 30 min of 
administration by diluting DSP in saline. During control treatment horses 
received the same volume of saline solution as their respective dexamethasone 
treatment. Before the bolus dose (time = 0), a pre-dose blood sample was 
collected. Additional blood samples were drawn during and after infusion at 
hours 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 36 and 48. A minimum of a one-week wash-
out period was allowed between drug treatments. 
In Papers III and IV the experiment had a prospective, randomized and 
blinded cross-over design, with two treatments. An overview of the experi-
mental set up is shown in Figure 1. In each treatment inflammation was 
induced into the antebrachiocarpal joint by means of LPS from Sigma-Aldrich 
(E Coli 055:B5). The LPS was diluted with 0.9% saline to give a concentration 
of 1 ng∙mL-1. A total volume of 2 mL of LPS solution was injected into the joint 
at time 0. Two hours after LPS injection, either 2 mL dexamethasone solution 
(DSP diluted in 0.9 % saline) or an equivalent volume of control solution (0.9 
% saline) were injected into the joint. The six horses used in the studies 
received individual doses dexamethasone. The dose levels were 0.01, 0.03, 0.1, 
0.3, 1 and 3 mg per joint. A minimum of a three weeks wash-out period was 
applied between treatments. Synovial fluid and blood samples were collected at 
0 (pre-LPS), 2, 4, 6, 10, 24, 28, 32, 48, 52, 56, 72, 76 hours. Three additional 
blood samples were drawn at 5, 20 and 40 minutes after dexamethasone/saline 
injection.  
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Figure 1. Overview of the time points of injections, sampling and clinical endpoint data collection 
(arrows) in paper III and IV.  A total volume of 2 mL containing 2 ng lipopolysaccharides was in-
jected in the antebrachiocarpal joint at 0h (L). At 2 h, dexamethasone sodium phosphate or saline 
was injected in the joint in a cross over design consisting of 2 treatments (T). Three extra blood-
samples were collected 5, 20 and 40 minutes after dexamethasone or saline injections (B). 
Clinical endpoints were recorded at one extra time point 8 h after LPS administration (CE). 
In Paper IV, data collection on clinical endpoints (CE) was as follows: The CE 
baseline was recorded three times on the day before LPS challenge. Various CE 
were also recorded before collection of synovial fluid and at one additional 
occasion eight hours after LPS administration. The CE were: rectal temperature 
(RT) measured by means of a digital thermometer, local skin temperature (ST) 
measured by means of a digital infrared thermometer (Fluke 574 cf, SR 
Automation AS, Asker, Norway) and joint circumference (JC) measured using 
a measuring-tape. Lameness was evaluated in trot (8 x 20 m in a straight line 
on flat concrete indoors). Lameness was subjectively scored by experienced 
clinicians by means of the American Association of Equine Practitioners 
(AAEP) lameness scale and objectively scored by means of an inertial sensor 
system-based method (Lameness Locator®, Equinosis, St. Louis, Missouri, 
USA). Before lameness evaluation one single axis accelerometer was attached 
to the bridle, one single axis accelerometer was attached between the right and 
left Tuber sacrale and one single axis accelerometer was attached to the dorsal 
aspect of the proximal phalanx of the right forelimb. Lameness was considered 
to be present when the minimum head height difference in vertical movement 
(MHH) between the stand phase of the right and left forelimb was greater than 
or equal to 7 mm and the average score for the study occasion was greater than 
its corresponding standard deviation. Non-lame Lameness Locator® (LL) scores 
were considered consistent with baseline data. 
4.3 Analytical methods 
4.3.1 Dexamethasone in plasma, urine and synovial fluid (paper I, II and III) 
and cortisol (hydrocortisone) in plasma (paper I and II) 
Dexamethasone concentrations in plasma, urine and synovial fluid and cortisol 
plasma concentrations were determined with the use of Ultra High 
0 20 30 40 5010 60 70 80
TL B CE
Time (h)
Papers III+IV
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Performance Liquid Chromatography-Tandem Mass Spectrometry (UHPLC-
MS/MS). Dexamethasone reference compound was acquired from Toronto 
Research Chemicals (North York, ON, Canada) and the internal standard 2H4-
dexamethasone (dexamethasone-d4) was purchased from CDN Isotopes 
through QMX Laboratories Ltd. (Essex, UK). Hydrocortisone and 2H4-
hydrocortisone (hydrocortisone-d4) were bought from Sigma-Aldrich (S:t 
Louis, MO, USA). The water was purified using a Milli-Q water purification 
system (Millipore, Bedford, MA, USA). All other chemicals were of analytical 
grade or better and used without further purification. The Lower Limit of 
Quantification (LLOQ) for dexamethasone was 0.025 ng∙mL-1 in plasma, 0.15 
ng∙mL-1 in urine and 0.38 ng∙mL-1 in synovial fluid. The precision, expressed 
as the relative standard deviation (RSD), in the results for quality control 
samples in plasma was 3.0-11.8% for dexamethasone and 0.5-9.7 % for 
hydrocortisone while for dexamethasone in urine it was 3.1-13.3 % and in 
synovial fluid 2.7-7.8 %. The analytical method used for analyses in plasma 
and urine is described in detail in Paper I and that used for analyses in synovial 
fluid in Paper III. 
4.3.2 Cortisol analyses in plasma (paper III) 
For cortisol analyses a commercial Enzyme Linked Immunosorbent Assay 
(ELISA) was used (Cortisol ELISA (DE1887), DEMEDITEC, Kiel, Germany). 
This ELISA is intended for human plasma but the analysis has previously been 
described and validated for equine plasma (Boman, 2013). The optical density 
was measured at 450 nm using a microtitere plate reader (Wallac Victor², 1420 
Multilabel Counter, Wallac Sverige AB). The cortisol concentrations were 
calculated by fitting a function to the optical densities by means of four 
parameter logistic fit using free online software from myAssays.com. The 
inter- and intra-test variation expressed as RSD, was 4 % and 11 % respectively. 
4.3.3 Interleukine-1β analyses in synovial fluid (paper III)  
For IL-1β analyses, a commercial ELISA (Equine IL-1β VetSet, Kingfisher 
Biotech, St. Paul, MN, USA) was used following the manufacturer’s 
instructions. The optical density was measured and concentrations calculated 
as described for cortisol. To confirm assay usefulness in sample matrix, 
synovial fluid was spiked to 10 and 50 ng∙mL-1. Spiked samples were applied 
in duplicates and quantified to 8.45 and 10.70 for the 10 ng∙mL-1 samples and 
50.85 and 59.05 for the 50 ng∙mL-1 samples. To assess inter-assay variability 
one sample was analysed on 8 occasions. To assess intra-assay variability one 
sample was analysed 9 times on 1 occasion.The inter- and intra-assay precision 
expressed as RSD was 30 % and 15 %, respectively. 
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4.4 Pharmacokinetic and pharmacodynamic concepts 
Experimental dexamethasone data were described using compartment models 
in the respective studies. The predicted dexamethasone-time courses then 
served as constants ‘driving’ the PD models (Figure 2)  
 
Figure 2. Schematic illustration of the disposition, drug mechanism function and response models 
used in Paper I (A), Paper II (B), Paper III (C) and Paper IV (D). Dose is the dose injected, Cp and 
Cs, are the dexamethasone concentration in plasma and synovial fluid, respectively; ka and k are 
the absorption rate constant (from muscle to plasma) and the elimination rate constant of 
dexamethasone, respectively; and Vc,Vt,Cld and Cl are the volume of the central and peripheral 
compartment, the distributional parameter and the clearance respectively. In disposition from 
synovial fluid to plasma kaF is the absorption rate constant with the bioavailability nested; kin and 
kout are the turnover rate and the fractional turnover rate of response; I(C) is the drug mechanism 
function; LPS is the challenge function; Rcor is the cortisol response, RIL-1β is the IL-1β response 
and RLL is the lameness response. In Paper II (B) one transit compartment (shaded) was used to 
capture the delayed onset of response. 
4.4.1 Exposure of dexamethasone in plasma 
In Paper I, a model including first order uptake and first order elimination was 
fitted to experimental dexamethasone concentration-time data. Exposure of 
dexamethasone in plasma (Cp) was described as 
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where A is a pharmacokinetic macro parameter and ka, k are the rate constants 
of the initial and terminal phase, respectively. The half-life of the terminal 
phase (t1/2z) was calculated as 
 
????? ? ??? ???        (2) 
 
A two compartment model was simultaneously fitted to the dexamethasone 
concentration-time data from all dose levels in Paper II. The disposition of 
dexamethasone in the central compartment was described as 
 
 ?? ? ????? ? ??? ? ?? ? ?? ? ??? ? ?? ? ??? ? ??    (3) 
 
where Ct denote the dexamethasone concentration in the peripheral compart-
ment, Vc  is the central volume of distribution,  Inf  is the dose infused, Cl is the 
clearance of dexamethasone and Cld is the inter-compartmental distribution. 
The peripheral compartment was described as 
 
 ?? ? ????? ? ??? ? ?? ? ??? ? ??                          (4) 
 
where Vt  is the peripheral volume of distribution. The effective half-life in 
plasma was calculated as 
 ???? ? ??? ?? ?????        (5) 
where Vss (=Vc + Vt) denotes the apparent volume of distribution at steady-state. 
In Paper III the input function of the two compartment model was adjusted 
to fit input to plasma from synovial fluid. The input function was described as 
 
????? ? ?? ? ???     (6) 
 
Where Cs is the dexamethasone synovial fluid concentration and kaF is the 
absorption rate constant with the bioavailability nested within the parameter. 
Hence, disposition of dexamethasone in the central compartment was described 
as 
 
  ?? ? ????? ? ????? ? ?? ? ?? ? ??? ? ?? ? ??? ? ??    (7) 
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The disposition of dexamethasone in the peripheral compartment was 
described with Equation 4. 
4.4.2 Exposure of dexamethasone in synovial fluid 
Dexamethasone exposure in synovia following the 0.01, 0.03, 0.1 and 0.3 mg 
dose was described as 
 
?? ? ???? ? ? ? ?????     (8) 
 
where Cs is the dexamethasone concentration in synovia, t is the time (in 
hours) and A and k are a pharmacokinetic macro parameter and the elimination 
rate constant respectively. Dexamethasone exposure in synovia following the 1 
and 3 mg doses was described as 
 
?? ? ???? ? ? ? ????? ? ???? ? ? ? ?????   (9) 
 
where A and B, are the pharmacokinetic macro parameters and α and β the 
initial and the terminal slope factors, respectively. 
4.4.3 Cortisol response 
Cortisol turnover rate is inhibited by dexamethasone. The inhibitory drug 
mechanism function I(Cp) is described by: 
 
 ????? ? ? ? ???????
?
????? ????
     (10) 
 
where Imax, IC50 and n are the maximum drug-induced inhibition, the 
dexamethasone plasma concentration at 50% of drug-induced suppression of 
cortisol and the sigmoidicity factor respectively (Hill, 1910; Wagner, 1968).  In 
Paper I, the turnover of cortisol response, R, was described as 
 
 ???? ? ??? ? ???? ? ?        (11) 
 
where dR/dt, kin and kout are the rate of change in response over time, the 
turnover rate and the first-order fractional turnover rate, respectively (Rescigno 
& Segre, 1966; Dayneka et al., 1993). Baseline of response, R0, was described 
as 
 
?? ? ???????      (12) 
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The turnover rate was implemented as a function of the baseline R0 and 
fractional turnover rate kout. 
 
??? ? ?? ? ????               (13) 
 
The drug mechanism function (Equation 10) was then incorporated into 
Equation 11 to give Equation 14 
 
 ???? ? ?? ? ???? ? ?? ?
????????
????? ????
? ? ???? ? ?    (14) 
 
In Papers II and III the circadian turnover rate kin(t) was approximated by a 
cosine function described as 
 
?????? ? ?????? ? ????? ? ??? ????? ? ?? ? ????? ? ? ?????
 
where kmean, αcirc, t and t0 are the mean input rate, amplitude, clock time within 
the 24 h cycle and peak time, respectively. The ratio 2∙π/24 converts the 24 h 
period into radians. In Paper II one transit compartment was used in the PD 
model. Hence, the turnover of cortisol with the drug mechanism function 
incorporated was described as 
 
?
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?? ? ??????? ? ?? ?
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   (16) 
 
where dR1/dt and dR2/dt are the rate of change of response in respectively 
compartment 1 and 2 of the turnover model. R1 and R2 denote the cortisol 
response and cortisol mean in plasma. The transit compartment model was not 
used in paper III. Hence, the turnover of cortisol with the drug mechanism 
function incorporated was described as 
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????????
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4.4.4 Lipopolysaccharide (LPS)-challenge model 
In Papers III and IV a time dependent stimulator function (SLPS) acting on the 
input rate of biomarker response was used. This approach was recently 
reviewed by Gabrielsson et al. (2015) and described as 
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where ALPS and kLPS represent the amplitude and the rate constant, respectively, 
of the stimulatory function due to the LPS-challenge. 
4.4.5 Interleukin-1β and lameness response 
The time course of the Interleukin-1β (IL-1β) response in synovial fluid (Paper 
III) and lameness response (Paper IV) as a result of the LPS-challenge was 
described as 
 
??
?? ? ???? ? ???? ? ?      (19) 
 
Dexamethasone was assumed to inhibit IL-1β syntheses and lameness. The 
inhibitory function for IL-1β was described as 
 
????? ? ? ? ?????????      (20) 
 
The time course for IL-1 β response with the drug mechanism function 
incorporated is then described as 
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and the inhibitor function for lameness response was described as 
 
????? ? ??????????????     (22) 
 
where Ainhib is a parameter relating change in drug concentration to change in 
response. The time course for lameness response with the drug mechanism 
function incorporated was then described as 
 
??
?? ? ????
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where γ is an exponent of the stimulatory challenge function. The concen-
tration of dexamethasone (Cs,50) that causes 50 % suppression of lameness 
response was calculated as 
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????? ? ???????       (24) 
The equilibrium concentration-response relationship at steady state for cortisol 
was described as  
 
 ??? ? ??? ? ?? ? ???????
?
????? ????
?      (25) 
 
and for lameness response as 
 
 ??? ? ? ???????? ?
?
?????????????
      (26) 
4.5 Statistical calculations 
In Paper I, the change in cortisol response over time was compared against R0 
using one-way ANOVA. Dunnett’s test was used for post hoc analyses.  
Statistic calculations in Paper I were performed using computer software 
(Minitab 16.2.2, Minitab Inc., State College, Pennsylvania, U.S.A.). 
In Paper IV, the area under the curve from all clinical endpoints from 
baseline to last observation ( ???????? ) was calculated by means of the 
trapezoidal method using WinNonlin 4.0.1. As baseline value (t=0), the mean 
of all baseline observations was used. The data were then subjected to 
statistical hypothesis testing by means of two-sided Wilcoxon Rank Sum test 
for paired data observations using the statistical software R version 3.2.2 (The 
R Foundation for Statistical Computing, Vienna, Austria). Clinical endpoint 
data from all dexamethasone doses were pooled before analyses. Statistical 
significance was considered if the p-value was smaller than 0.05. 
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5 Results and Discussion 
5.1 Exposure to dexamethasone (Papers I, II and III) 
5.1.1 Dexamethasone-21-isonicitinate intramuscularly 
In Paper I, 0.03 mg∙kg-1 dexamethasone-21-isonicotinate was administered 
intramuscularly to six horses. The main reason for quantifying dexamethasone 
plasma and urine concentrations was to obtain information of the dexametha-
sone concentration-time profile in plasma and urine to be used as support when 
estimating DT for equine athletes. The main reason for modelling experimental 
plasma dexamethasone-time data was to generate concentration-time profiles 
that could serve as input to the inhibiting function of the PD model. 
 Exposure in plasma 
In plasma, observed peak concentration of dexamethasone was (mean ± 
standard deviation) 0.61 ± 0.12 ng∙mL-1. Maximum concentrations were ob-
served between 12 and 24 hours post drug administration (Figure 3). 
Dexamethasone was quantifiable (LLOQ 0.025 ng∙mL-1) in plasma for up to 13 
days (mean ± standard deviation: 8.3 ± 2.9 days). There was a two-fold 
variation in absorption rate and three-fold variation in elimination rate of 
dexamethasone in plasma (Table 2). The variation in elimination rates is also 
reflected in the calculated terminal half-life (t1/2z) for dexamethasone in plasma 
which ranged between 18.8- and 58.6 hours for the six horses. This variation in 
half-life was also obvious considering the variation in time between drug 
administration and time when plasma concentrations dropped below the LLOQ 
for the six horses, as seen in Figure 3.  
The plasma dexamethasone concentration-time profiles obtained in Paper I 
were different from those in Paper II. The differences were not due solely to 
the obvious absence of an absorption phase after use of the iv route of 
administration in Paper II. The mean terminal half-life after im administration 
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was 39 hours. This can be compared with the median effective half-life of 2.4 
hours after iv administration used in Paper II. The pharmaceutic preparation of 
dexamethasone-21-isonicotinate used in Paper I is a suspension due to its low 
water solubility and acts as a slow release formulation. The prolonged and 
variable terminal half-life values reflect the slow release into plasma from the 
injection site (Gibaldi & Perrier, 1982). 
A one-compartment model was fitted to the experimental data. In Paper I, 
some quantitative information on the slow release formulation of the drug was 
provided (input and output rate). The maximum observed plasma concentration 
was lower and the terminal phase extended compared with the concentration-
time profile obtained after im administration of dexamethasone sodium 
phosphate solution (Soma et al., 2013). However, the study presented in this 
thesis was not a complete PK study due to the fact that no iv data were 
obtained.  
Table 2. Model estimated and derived parameters of dexamethasone exposure in plasma after 
0.03 mg·kg-1 dexamethasone-21-isonicotinate administered intramuscularly to six horses 
 Model parameters Derived parameter 
Horse A (ng∙mL-1) k (h-1)  ka (h-1) t1/2z (h) 
1 2.05 0.03 0.08 27.1 
2 0.88 0.02 0.11 43.0 
3 0.49 0.01 0.15 70.1 
4 0.80 0.01 0.10 48.7 
5 1.40 0.03 0.08 25.2 
6 2.50 0.03 0.06 23.4 
Mean ± SD 1.37 ± 0.81 0.02 ± 0.01 0.10 ± 0.03 38.7 ± 19.0 
95% CI 0.52 - 2.22 0.01 - 0.03 0.06 - 0.13 18.8 - 58.6 
A is a pharmacokinetic macro parameter, k and ka are the elimination rate constant and the 
absorption rate constant and t1/2z is the terminal half-life. 
Exposure in urine 
In urine, observed peak concentration of dexamethasone was (mean ± standard 
deviation) 4.2 ± 0.9 ng∙mL-1 and was observed between 22 and 36 hours post 
drug administration (Figure 3). Dexamethasone was quantifiable in urine 
(LLOQ 0.15 ng∙mL-1) for up to 14 days (mean ± standard deviation: 9.8 ± 3.1 
days). Inspection of the curves in Figure 3 indicates that the dexamethasone 
concentration-time profiles in plasma and urine were similar. Urine conc-
entrations peaked later and were in median 7-fold higher and more variable, 
both within and between individual horses. The variability in dexamethasone 
urine data was about 2- to 4-fold higher than that in dexamethasone plasma 
data. 
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Figure 3. Semi-logarithmic plot of observed urine (solid lines) and plasma (dashed lines) 
dexamethasone concentration-time courses after 0.03 mg∙kg-1 dexamethasone-21-isonicotinate 
administered intramuscularly to six horses. Horizontal lines denote the lower limit of quanti-
fication (LLOQ) in plasma (dashed line) and urine (solid line) respectively. The urine 
concentration-time course appears to be related to the plasma concentration-time course, which is 
illustrated by Horse 1 and Horse 3. 
5.1.2 Dexamethasone-21-sodium phosphate salt intravenously 
The main reason for quantifying and modelling dexamethasone plasma 
concentrations in Paper II was to characterise the disposition of dexamethasone 
in Standardbreds and to provide individual concentration-time profiles that 
could serve as input to PD analyses.  
Dexamethasone disposition was linear within the studied concentration and 
time range and the concentration-time courses from all horses were similar 
(Figure 4). The two-compartment model accurately mimicked experimental 
data (Figure 5) and model parameters were estimated with good to acceptable 
precision. The parameter values were in median (range): 0.98 L∙kg-1 (0.42-
1.16), 0.82 L∙kg-1 (0.53-1.11), 0.51 L∙h-1∙kg-1 (0.46-0.56) and 0.2 L∙h-1∙kg-1 
(0.1-0.51) for Vc, Vt, Cl and Cld, respectively. The effective half-life, which is a 
measure of total removal of the drug from all compartments, was 2.4 h (2.0-
2.6). Individual parameter estimates are given in Table 3. The parameters 
showed low variability between animals which is consistent with previous 
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findings in studies on Thoroughbreds (Cunningham et al., 1996; Soma et al., 
2005; Grady et al., 2010; Soma et al., 2013).  
 
 
Figure 4. Semi-logarithmic plot of dexamethasone plasma concentration-time data during and 
after a bolus dose followed by three hours constant rate infusion of dexamethasone sodium 
phosphate to six horses. The dose levels were (bolus + constant rate infusion) 0.1 + 0.07 μg∙kg-1, 
1 + 0.7 μg∙kg-1and 10 + 7 μg∙kg-1. 
 
 
Figure 5. Semi-logarithmic plot of observed (symbols) and model predicted (lines) dexa-
methasone plasma concentration-time data for two horses given three different dose levels of 
dexamethasone. The dose levels were (bolus + three hours constant rate infusion regimen) 0.1 + 
0.07 μg∙kg-1  (filled squares, dotted lines), 1 + 0.7 μg∙kg-1 (filled circles, dashed lines) and 10 + 7 
μg∙kg-1  (filled diamonds, solid lines). 
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Table 3. Model estimated and derived pharmacokinetic parameters after a bolus dose followed by 
three hours of constant rate infusion of dexamethasone sodium phosphate administered intra-
venously to six horses. 
Vc and Vt are the central and the peripheral volume of distribution, Cl is the clearance, Cld is the 
inter-compartmental distribution, Vss is the apparent volume of distribution at steady-state and t1/2 
is the effective half-life of dexamethasone. 
5.1.3 Dexamethasone-21-sodium phosphate salt intraarticularly 
Exposure in synovial fluid 
Observed dexamethasone synovial fluid and plasma concentrations are shown 
in Figure 6. In synovial fluid collected after ia administration of dexametha-
sone in doses of 0.01, 0.03, 0.1 and 0.3 mg, dexamethasone was only 
quantified in concentrations above the LLOQ for synovial fluid (0.375 ng∙mL-1) 
up to 8 hours (three samples) after DSP injection. In synovial fluid collected 
after the 1 mg and 3 mg doses dexamethasone was quantified up to 30 hours 
(six samples) after DSP injection. 
To experimental data from the 0.01, 0.03, 0.1 and 0.3 mg dose levels, a one-
compartment model was fitted. To experimental data from the 1 and 3 mg 
doses, a two-compartment model was fitted. Observed and model predicted 
dexamethasone synovial fluid and plasma concentration-time courses are 
shown in Figure 7 for two of the horses. The sparse experimental data from the 
four lower doses only allowed fitting of a one-compartment model to the data- 
set. It is possible that higher doses DSP or a more sensitive analytical method 
than used in this work could have revealed a bi-phasic decline in the 
dexamethasone synovial fluid concentration-time course also in these horses. 
The model-estimated and derived PK parameters are shown in Tables 4 and 5. 
The area under the dexamethasone synovial fluid concentration-time curve 
(AUC) was 90, 550, 2 400, 7 600, 11 000 and 30 000 ng∙mL-1∙h-1 for the 0.01, 
 Model parameters  Derived parameters 
 
Horse 
Vc 
(L∙kg-1) 
Vt 
( L∙kg-1) 
Cl 
( L∙h∙kg-1) 
Cld 
( L∙h∙kg-1) 
 Vss 
( L∙kg-1) 
t1/2 
(h) 
1 1.16  0.76  0.56  0.19   1.92 2.4 
2 0.42 1.11  0.46  0.51   1.52 2.3 
3 0.75  0.81  0.48  0.22   1.56 2.3 
4 0.98  0.53  0.53  0.10   1.51 2.0 
5 0.97  0.82  0.47  0.21   1.79 2.6 
6 1.12  0.89  0.55  0.13   2.01 2.5 
Range 0.42-1.16 0.53-1.11 0.46-0.56 0.10-0.51  1.51-2.01 2.0-2.6 
Median 0.98 0.82 0.51 0.20  1.58 2.4 
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0.03, 0.1 0.3, 1 and 3 mg doses respectively. The median (range) volume of 
synovial fluid cleared from dexamethasone was 71.4 mL∙h-1 (39.5-113.2).  
 
Figure 6. Spaghetti plot of observed synovial fluid (solid lines) and plasma (dashed lines) 
dexamethasone concentrations over time. Six horses were treated with different doses of 
dexamethasone sodium phosphate intraarticularly (DEX) two hours after intraarticular injection of 
2 ng lipopolysaccharides (LPS). The doses were 0.01, 0.03, 0.1, 0.3, 1 and 3 mg dexamethasone. 
Dexamethasone was not quantifiable in plasma from the horse treated with 0.01 mg dexametha-
sone. The first synovial fluid sample was collected two hours after dexamethasone injection. The 
first plasma sample was collected 5 minutes after dexamethasone injection. 
The terminal half-life (t1/2z) for dexamethasone in inflamed synovial fluid 
ranged from 0.9 to 3.3 hours after ia administration of DSP. This is similar to 
the half-life in plasma after iv administration of DSP (Grady et al., 2010). A 
tentative stability control in the laboratory showed that the DSP ester is cleaved 
more rapidly in inflamed synovial fluid compared with synovial fluid from a 
healthy joint 1 . The inflammatory process cause increased blood flow and 
permeability over the vascular endothelium (Owen & Farrington, 1976). This 
might increase the distribution of dexamethasone into plasma. Conclusively, it 
is possible that the half-life in synovial fluid from a healthy joint would be 
longer. However, there is no dexamethasone half-life in synovial fluid from 
healthy joints reported, so this is pure speculation. 
                                                        
1 . Mikael Hedeland Head of Department of Chemistry, Environment and Feed Hygiene 
National Veterinary Institute, e-mail 2014 04 01 
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Figure 7. Observed (symbols) and model-predicted (lines) dexamethasone concentration-time 
courses in synovial fluid (left) and plasma (right) from two horses treated with individual doses 
(0.01 mg, empty circles, dashed lines and 3 mg, filled circles, solid lines) of dexamethasone 
injected into the antebrachiocarpal joint. 
Table 4. Model predicted and derived pharmacokinetic parameters describing exposure in 
synovial fluid following intraarticular administration of dexamethasone sodium phosphate to four 
horses. The parameters are estimated by means of a one-compartment pharmacokinetic model. 
 Model parameters Derived parameter 
Dose  A1   k   t1/2z  
(mg) (ng∙mL-1)   (h-1)   (h) 
0.01     50 0.54 1.3 
0.03   300 0.55 1.3 
  0.1 1900 0.80 0.9 
  0.3 5700 0.76 0.9 
A is a pharmacokinetic macro parameter, k is the elimination rate constant and t1/2z is the terminal 
half-life. 1 Parameter value reported with the dose incorporated 
Table 5. Model predicted and derived pharmacokinetic parameters describing exposure in 
synovial fluid following intraarticular administration of dexamethasone sodium phosphate to two 
horses. The parameters are estimated by means of a two-compartment pharmacokinetic model. 
 Model parameters Derived parameters 
Dose 
(mg) 
A1 
(ng∙mL-1) 
B1 
(ng∙mL-1) 
α 
(h-1) 
β 
(h-1) 
t1/2α 
(h) 
t1/2β 
(h) 
1 11000   310 1.07 0.21 0.6 3.4 
3 13000 2400 0.70 0.22 1.0 3.2 
A and B are pharmacokinetic macro parameters, α and β are the slope factors and t1/2α and t1/2β  the 
half-life of the initial and the terminal phase. 1 Parameter value reported with the dose 
incorporated 
 
The dexamethasone synovial fluid-time courses after ia administration of 10 
and 25 mg DSP were simulated using model parameters based on experimental 
data obtained from the 1 and the 3 mg doses (Figure 8). Increasing the dose 
C
on
ce
nt
ra
tio
n
(n
g∙
m
L-
1 )
Time (h)
0.1 mg
0
0.1
1
10
102
103
104
105
3 mg
10 20 30 5040
Synovial fluid
0.1 mg
0
0.1
1
10
3 mg
10 20 30 40
0.01
Plasma
40 
increased the time above the LLOQ for the analytical method. The terminal half-
life of dexamethasone in synovial fluid is relatively short (0.9-3.4 h). 
Therefore, a relatively high increase in dose would probably produce a 
relatively small increase in duration of response. 
 
Figure 8. Semilogarithmic 
plot of the simulated dexa-
methasone synovial fluid 
concentration-time courses 
following intraarticular ad-
ministration of 10 mg and 
25 mg dexamethasone to 
two horses. Model para-
meters obtained from the 1 
mg and 3 mg dose experi-
mental data were used in 
simulations. Horizontal li-
nes indicate the tentative 
potency (IC50) range for 
IL-1β response. 
 
Exposure in plasma 
Dexamethasone was quantified (LLOQ 0.025 ng∙mL-1) in plasma from five 
horses (Figure 6). It was not possible to quantify dexamethasone in plasma 
from the horse injected with the lowest dose of dexamethasone (0.01 mg). 
Following the 0.03 mg dose, dexamethasone concentration was quantified in 
plasma in two samples. These samples were collected 5 and 20 minutes after 
DSP injection and the dexamethasone concentration in both was quantified to 
0.03 ng∙mL-1. Following the 0.1, 0.3, 1 and 3 mg doses, dexamethasone 
concentrations was quantified in 5-7 samples for up to 24 hours. The dexa-
methasone plasma concentrations were consistently lower than the synovial 
fluid concentrations (Figure 6). Two hours after dexamethasone injection ia, 
synovial fluid concentrations were 3000-10000 fold higher than plasma 
concentrations. At the time of the last sampling in which dexamethasone 
concentration exceed the LLOQ in plasma, the synovial fluid concentrations 
were 200-1000 fold higher than the corresponding plasma concentrations. 
Maximum observed dexamethasone plasma concentration was observed within 
40 minutes after dexamethasone injection into the joint. This together with the 
short terminal half-life (0.9-3.4 h) for dexamethasone in synovial fluid suggests 
rapid distribution from the joint into plasma after ia injection of DSP. 
A two-compartment model with synovial fluid input to plasma was fitted to 
experimental dexamethasone plasma data for the four higher doses. The model 
0.1
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accurately mimicked experimental data (Figure 7). The main reason for 
modelling the plasma dexamethasone-time course after ia administration of 
DSP was to investigate the systemic exposure with respect to the cortisol 
response and to simulate the dexamethasone plasma concentration-time 
courses after higher doses DSP administered into the joint. Therefore, low 
parameter precision in the analyses was accepted. The parameter estimates 
were fixed and used as constants ‘driving’ the PD model and the simulations.  
5.2 Response to dexamethasone exposure (Paper I-IV) 
5.2.1 Cortisol response (Paper I, II and III) 
Cortisol baseline 
Cortisol plasma concentrations has often been used as a response biomarker to 
dexamethasone exposure in horses and other domestic species, e.g. dogs, cats 
and cattle (Toutain et al., 1982; Toutain et al., 1983; Toutain et al., 1984; 
Smith & Feldman, 1987; Soma et al., 2005; Abraham et al., 2009; Grady et al., 
2010) The use of an integrative approach with quantitative methods in this 
thesis allowed separation of the drug properties (IC50, Imax and n) from the 
physiologic system properties (kout , t0, αcirc and R0). Quantitative analyses of 
cortisol response in Paper I was a secondary aim that mainly served to collect 
information as input to Paper II. The unaffected cortisol baseline in Papers II 
and III was characterised by a circadian variation with peak concentration in 
the morning and nadir concentrations in the afternoon/evening (Figure 9). In 
Paper I, data does not suggest circadian variation (Figure 10). This was due to 
the experimental protocol as all blood samples without dexamethasone present 
in the system were collected at 9 a.m. In addition, Paper I did not include any 
cortisol response data after control treatment with e.g. saline. As a consequence 
of the difference in experimental design and perhaps due to variation between 
study populations, the unaffected baseline of cortisol response appeared higher 
in Paper I compared to Papers II and III. The unaffected baseline range was 76-
109 ng∙mL-1 in Paper I, 34-57 ng∙mL-1 in Paper II and 41-81 ng∙mL-1 in Paper 
III. However, literature data indicate between study variations in cortisol 
baseline in horses that can be due to differences in study design and study 
populations (Toutain et al., 1988b; Soma et al., 2013). The results in those 
studies the results are consistent with the results from Paper II if the oscillation 
in cortisol baseline data is described by means of a cosine function. When the 
experimental design was similar to the design in Paper I, reported baseline data 
from the literature were also consistent with data given in Paper I.  
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Figure 9. Spaghetti plot of observed cortisol-time courses during treatment with saline from six 
horses included in paper II (left) and six horses included in paper III (right).   
Within animal variation in the cortisol baseline was observed. It is possible that 
external factors (stress or handling of the horses) stimulated cortisol release 
into plasma (Irvine & Alexander, 1994; Fazio et al., 2008). Cortisol is 
episodically released into plasma which together with the relatively short half-
life of the fractional cortisol turnover rate causes variation within the individual 
cortisol response-time courses (Toutain et al., 1988a; Lassourd et al., 1996). 
This might also explain the variation observed in this thesis.  
The amplitude parameter (αcirc) was in median (range) 9.2 (6.8-24) in paper 
II and 16.2 (4.5-42.4) in paper III. Apart from physiology external factors, e.g. 
stress and handling of the horses also have an impact on this parameter (Irvine 
& Alexander, 1994; Fazio et al., 2008). It has been suggested that the circadian 
rhythm is easily obliterated in horses  (Irvine & Alexander, 1994). In both 
Paper II and Paper III a circadian variation in the time-dependent cortisol 
response baseline (R0) was observed. This finding suggests that it is possible 
that the variation in amplitude parameter reported in this thesis is mainly a 
result of physiological variations between the different horses studied and not a 
result of external factors. 
To mimic the circadian variation of cortisol response a cosine function was 
used. Similar functions have been applied in PD models fitted to cortisol 
response data in humans (Lew & Jusko, 1993; Chakraborty et al., 1999). 
Median peak time of the cosine function (t0) ranged from -2.8 to -4.7 and -0.2 
to -5.8 in Paper II and Paper III, respectively. Start time for both experiments 
was between 9 and 10 a.m. Peak time of the circadian function in the morning 
was consistent with the literature (Hoffsis et al., 1970; Bottoms et al., 1972; 
Larsson et al., 1979; Toutain et al., 1988b; Hart et al., 2012; Bohak et al., 
2013). The fractional turnover rate (kout) range was 0.16-0.71 h-1, 0.47-1.5 h-1 
and 0.14-1.24 h-1 in Paper I, II and III, respectively. The parameter varied 3- to 
8- fold within studies and showed low variation between studies. The kout 
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parameter gave a half-life of response ranging from 0.4 h to 4.2 h, which is 
consistent with values presented elsewhere (Lassourd et al., 1996; Soma et al., 
2005; Soma et al., 2013). 
 
 
Figure 10. Semi-logarithmic plots of observed and model predicted cortisol and dexamethasone 
plasma concentration-time courses before and after intramuscular administration of 0.03 mg∙kg-1 
dexamethasone-21-isonicotinate (Dex) at time 0 (9 a.m.). Left plot (A): Spaghetti plot of observed 
cortisol-time courses (solid lines) and dexamethasone-time curses (dashed lines) in six horses. 
Right plot (B): Observed and model predicted cortisol-time courses (filled circles, solid lines) and 
dexamethasone-time courses (empty circles, dashed line) in one horse. 
Cortisol response to dexamethasone exposure 
In Papers I and II a clear dexamethasone concentration-cortisol response 
relationship was described and quantified in all horses (Figures 10, 11 and 12, 
Table 6). When dexamethasone became systemically available (i.e. in plasma) 
cortisol concentrations started to decrease. Cortisol response was suppressed 
until plasma dexamethasone concentration fell below its respective IC50-value, 
whereupon cortisol response gradually returned to baseline. In Paper III, only 
data from the 1 mg and 3 mg doses DSP indicated response of cortisol to 
dexamethasone exposure (Figure 13). This was due to the low dexamethasone 
plasma exposure after ia injection of the lower doses. However, PD model 
parameters for those horses were consistent with parameters presented in 
Papers I and II. The PD model parameter estimates are shown in Table 6.  
In Paper II, the time dependent baselines of cortisol response with 
dexamethasone present in the system were in median (range) 48 ng∙mL-1 (33-
65), 43 ng∙mL-1 (27-66) and 35 ng∙mL-1 (17-51) for the low, intermediate and 
high dose, respectively. In Paper III, the time-dependent baseline of cortisol 
response with the drug present in the system were 52 ng∙mL-1 and 49 ng∙mL-1 
for data collected after ia administration of the 1 mg and 3 mg doses, 
respectively. 
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Figure 11. Left column: Predicted dexamethasone plasma-time courses after the low (A: 0.17 
μg∙kg-1), intermediate (B: 1.7 μg∙kg-1) and high (C: 17 μg∙kg-1) doses of dexamethasone infused 
over 3 h. The horizontal dotted lines indicate the predicted potency (IC50) range. Right column: 
Predicted cortisol response-time courses after the three concentrations of dexamethasone. The 
dashed grey lines denote the baseline-time course of the saline treatments. Arrows denote 
estimated duration of response. 
The presence of dexamethasone in the system suppressed cortisol response in 
all horses in Papers I and II. In Paper III, suppression of cortisol response by 
dexamethasone could only be detected in horses treated with the 1 mg and 3 
mg doses of dexamethasone. After the lower doses dexamethasone the 
systemic exposure of dexamethasone was insufficient to induce a level of 
suppression of cortisol response that could be detected using the current 
experimental protocol.  
Dexamethasone is a potent (low IC50 value) and effective (high Imax value) 
suppressor of cortisol response in horses (Table 6). The potency value (IC50-
parameter) ranged from 25 to 132 pg∙mL-1 in Paper I and from 6 to 65 pg∙mL-1 
in Paper II. In paper III the IC50-value was 43 pg∙mL-1 and 32 pg∙mL-1 for the 1 
mg dose and the 3 mg dose, respectively. The value of the Imax parameter 
ranged from 0.92-0.97 in Paper I and 0.77-0.97 in Paper II. In Paper III the Imax 
parameter was 0.77 for the 1 mg dose and 0.80 for the 3 mg dose. The n 
parameter gives the shape of the slope and is an indication of the sensitivity of 
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a physiological system. A high value of the n-parameter indicates a steep curve 
and an almost dichotomous concentration-response relationship. Consequently, 
at low concentrations a small increase in dexamethasone plasma concentration 
produces a large increase in cortisol response. At concentrations well above the 
IC50-value, a relatively large increase in concentration produces a relatively 
small increase in response (Figure 14). The main consequence of increasing the 
dose further is an increase in the duration of response, but not the intensity of 
response (Figures 11 and 14).  
 
Figure 12. Observed (symbols) and model predicted (lines) cortisol plasma concentration-time 
courses from two horses given a 3 hour infusion of dexamethasone at three different dose levels. 
Horse 1 (left) shows high and horse 4 (right) low amplitude in cortisol oscillation. The dose levels 
were 0.17 μg∙kg-1, (filled squares, dotted black lines), 1.7 μg∙kg-1 (filled circles, solid lines) and 
17 μg∙kg-1 (filled diamonds, dashed lines). Baseline is represented by grey triangles, solid grey 
lines. 
 
Figure 13. Observed (symbols) and model predicted (lines) cortisol plasma concentration-time 
courses from two horses injected with 1 mg (left) or 3 mg (right) dexamethasone (empty circles, 
dashed lines) or saline (filled circles, solid lines) intraarticularly at time=0. 
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Figure 14. Semi-logarithmic plots of plasma dexamethasone concentration-cortisol response 
relationship from paper I (solid lines) and paper II (dashed lines). Left: Absolute response where 
the arrow denotes variation in cortisol response baseline. Right: same data as the left hand plot but 
on a relative response scale where the arrow denotes the variation in potency. 
Clinical application of the quantitative cortisol response model 
One application of the quantitative PD model described in Paper II was to 
predict the outcome of one testing protocol and drug scheduling in the 
dexamethasone suppression test (Dybdal et al., 1994). This test is used in 
medical investigations to diagnose hyperadrenocorticism. Simulated duration 
of cortisol response was more than 20 hours in healthy Standardbreds after iv 
administration of 20 μg∙kg-1 dexamethasone (Figure 15). Cortisol response 
showed oscillating behaviour at maximum response. These oscillations at 
maximum drug effect were more pronounced in horses with larger amplitude 
(αcirc-parameter) in cortisol baseline oscillation than in horses with smaller 
αcirc-values. Cortisol response oscillated between 3-15 ng∙mL-1 in the high 
amplitude horse in the simulation. These results persisted with increased dose 
(40 μg∙kg-1). Horses with hyperadrenocorticism often suffer from hyper-
glycaemia and insulinaemia, which are also effects of dexamethasone (Keen et 
al., 2004; Tiley et al., 2007). Therefore, decreased doses of dexamethasone 
may lower the risk of additional unwanted effects due to high dexamethasone 
exposure. Duration of response after the iv dosage regimen of 20 μg∙kg-1 was 
satisfactory for the test, as can be seen in Figure 15. A test protocol based on a 
single plasma sample was not optimal due to the oscillating behaviour of 
cortisol response around the proposed threshold. This problem can be solved 
by more frequent sampling since time-series sampling for a quantitative 
assessment of the cortisol response would improve the quality of the test 
results. Additional samples, e.g. at 7 and 22 hours after dexamethasone 
administration, would capture the fluctuations in response more adequately 
than a single time point evaluation. If a single time point sample is used the test 
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results should be interpreted with caution due to the oscillating behaviour of 
cortisol. Use of the iv compared with the im route of administration increases 
the control of plasma exposure otherwise confounded by within- and between- 
individual variations in rate and extent of absorption and allows a lower dosage 
regimen. It should be noted that the median parameter estimates were used in 
simulations in this study. Individual patients may deviate even more from the 
predicted cortisol-time course. Reported values from the dexamethasone 
suppression test may therefore be different from the cortisol response presented 
here. Hence, this example merely exemplifies the power of model-based 
analyses. 
 
 
Figure 15. Simulated cortisol-time courses after a 20 μg∙kg-1 bolus dose of dexamethasone 
administered intravenously to a high amplitude horse (left) and a low amplitude horse (right). 
Arrows indicate the proposed injection time (17 pm) and sampling time (19 h post dexamethasone 
administration) proposed by Dybdal et al. (1994) for the dexamethasone suppression test. The 
horizontal lines indicate the proposed plasma cortisol threshold in the dexamethasone suppression 
test (10 ng∙mL-1). 
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5.2.2 IL-1β response (Paper III) 
LPS-challenge and changes in IL-1β concentration over time 
It was not possible to quantify IL-1β with the method used in this study in any 
of the pre-LPS administrations samples. During saline treatment, IL-1β was 
detected in concentrations above the assay LLOQ (3.125 ng∙mL-1) in synovial 
fluid samples from five horses collected between 2 and 10 hours after LPS 
administration (Table 7, Figure 16). Peak concentration during saline treatment 
was observed 4 hours after LPS administration and ranged between 10 ng∙mL-1 
and 51 ng∙mL-1. In the horse treated with 0.01 mg dexamethasone IL-1β was 
3.2 and 5.0 at 4 and 6 hours after LPS administration, respectively. After 
treatment with LPS + saline in the same horse, IL-1β was not above the LLOQ in 
any samples. During dexamethasone treatment IL-1β was above the assay 
LLOQ in samples from the 0.01, the 0.1 and the 0.3 mg dose with observed peak 
concentration 4 to 6 hours after LPS injection. The IL-1 β concentration was 
higher after treatment with 0.01 and 0.3 mg dexamethasone compared to 
respective treatment with saline. The IL-1β concentrations were lower after 
treatment with dexamethasone in horses receiving 0.03, 0.1, 1 and 3 mg doses 
compared with treatment with saline. 
 
Figure 16. Observed synovial fluid IL-1β concentration-time courses in six horses after intra- 
articular administration of 2 ng lipopolysaccharides (LPS) at hour 0 and dexamethasone sodium 
phosphate (empty circles) or saline (filled circles) at hour 2. The horses were treated with one 
dose each. The doses were 0.01 mg, 0.03 mg, 0.1 mg, 0.3 mg, 1 mg and 3 mg dexamethasone.  
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Synthesis of IL-1β is inhibited by dexamethasone at transcriptional level (Lee 
et al., 1988; Waterman et al., 2006; Hirsch et al., 2012). In addition, exposure 
to glucocorticoids decreases the stability of IL-1β mRNA and the release of IL-
1β (Snyder & Unanue, 1982; Lee et al., 1988; Waterman et al., 2006). Samples 
from two horses (treated with 0.01 mg and 0.3 mg dexamethasone) were found 
to have higher synovial fluid IL-1β concentrations after saline treatment 
compared with dexamethasone treatment. The most likely explanation is a 
combination of variability in LPS-challenge response between treatments, the 
low doses of dexamethasone administered (0.01 mg and 0.3 mg), potential 
incomplete injections of LPS or DSP and intra-assay variation in the analytical 
method. The strong evidence for dexamethasone induced inhibition of IL-1β 
synthesis combined with the data set in this thesis led to that experimental data 
from horses treated with 0.03, 0.1, 1 and 3 mg dexamethasone and respective 
saline treatment were used in modelling. 
Table 7. Observed synovial fluid IL-1β (ng·mL-1) concentrations before and after intraarticular 
administration of 2 ng lipopolysaccharides at time 0 and dexamethasone (Dex) or saline at 2 h. 
Six horses were used in a two-treatment cross over design experiment. The horses were treated 
with different doses of dexamethasone. 
 IL-1β (ng∙mL-1)  
Dose 0h 2h 4h 6h 10h 
(mg) Dex Saline Dex Saline Dex Saline Dex Saline Dex Saline 
0.01 <LLOQ <LLOQ <LLOQ <LLOQ 3 <LLOQ 5 <LLOQ <LLOQ <LLOQ 
0.03 <LLOQ <LLOQ <LLOQ <LLOQ <LLOQ 51 <LLOQ 44 <LLOQ 5 
0.1 <LLOQ <LLOQ <LLOQ 10 7 20 5 17 <LLOQ <LLOQ 
0.3 <LLOQ <LLOQ <LLOQ <LLOQ 17 10 20 10 4 4 
1 <LLOQ <LLOQ <LLOQ <LLOQ <LLOQ 21 <LLOQ 15 <LLOQ <LLOQ 
3 <LLOQ <LLOQ <LLOQ <LLOQ <LLOQ 28 <LLOQ 26 <LLOQ 7 
Pharmacodynamic model 
The sparse data set combined with lack of quantifiable IL-1β concentrations 
during treatment with 0.03, 1 and 3 mg dexamethasone made it impossible to 
fit the PD model to the individual IL-1β concentration-time courses. Therefore, 
data from the horses treated with 0.03, 0.1, 1 and 3 mg were modelled 
simultaneously (Figure 17). Data from each individual dexamethasone synovial 
fluid concentration-time course served as constants ‘driving’ the PD model 
fitted to the IL-1β experimental data. Hence, the variation in PD model 
parameter estimates does not reflect true between-individual variation. The 
model parameter estimates derived by simultaneously modelled IL-1β response  
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to these four dexamethasone-time courses were in median (range) 0.5 h-1 (0.49-
0.51), 19 ng∙mL-1 (7-45), 0.47 h-1 (0.47-0.47) and 51.9 ng∙mL-1 (51.6-52.3) for 
kout, IC50, kLPS and ALPS, respectively.  
 
Figure 17. Observed (symbols) and model predicted (lines) IL-1β synovial fluid-time courses in 
four horses after intraarticular injection of 2 ng lipopolysaccharides (LPS) at hour 0 followed by 
dexamethasone sodium phosphate (empty circles, dashed line) or saline (filled circles, solid lines) 
at hour 2. The four horses were treated with one dose of dexamethasone each. The doses were 
0.03, 0.1, 1, and 3 mg. 
5.2.3 Clinical response (Paper IV) 
In Paper IV the clinical endpoints JC (joint-circumference), ST (local skin 
temperature), RT (rectal temperature) and lameness, scored by both the AAEP 
(American association of equine practitioners)-score and LL (lameness locator)-
score, were used as biomarkers of clinical response. There was no difference in 
clinical response baseline between the two treatment protocols (LPS+ 
dexamethasone and LPS + saline).  
Lameness response 
The LPS-challenge + saline treatment increased lameness response score 
measured as difference in MHH (minimum head height) using LL data compared 
with baseline (Figure 18). The LL-response ???????? was lower in all horses 
after treatment with dexamethasone compared to treatment with saline. The LL-
score expressed as ????????  ranged from 150 to 2100 mm∙h after treatment 
with saline and from 10 to 440 mm∙h after treatment with dexamethasone The 
difference between the two treatment protocols using the LL-response scores 
was significant (P=0.03).  
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Figure 18. Spaghetti-plot of observed minimum head height relative to baseline scored by the 
lameness locator system in six horses challenged with 2 ng lipopolysaccharides (LPS) in the 
antebrachiocarpal joint at hour 0. At hour 2 either saline (solid lines) or dexamethasone (DEX, 
dashed lines) was injected in the LPS-challenged joint. The six horses received one dose of 
dexamethasone each. The doses were 0.01, 0.03, 0.1, 0.3, 1, and 3 mg.  
The LPS-challenge + saline treatment increased lameness response score using 
AAEP data compared with baseline in five of the six horses. The AAEP data 
collected after LPS-challenge + saline treatment from horse #6 (which was 
treated with 0.01 mg dexamethasone as active treatment) did not indicate 
lameness. Lameness response score expressed as AAEP ???????? ranged from 1 
to 30 degrees lameness∙h after treatment with dexamethasone and from 0 to 80 
degrees lameness∙h after treatment with saline. The AAEP lameness response 
score ???????? was lower after treatment with 0.03-3 mg dexamethasone, but 
not after the 0.01 mg dose compared with saline treatment. The difference 
between the different treatment protocols using the AAEP scores was not 
significant (p=0.21). In this thesis, the LL-score was more sensitive in detecting 
differences in lameness than the AAEP-score. In the LL-scoring system, the 
measured outcome variable can range from 0 to (in theory) infinity. The AAEP 
scale ranges from 0 to 5. This and the fact that the AAEP lameness score 
????????for the horse treated with 0.01 mg dexamethasone was lower than the 
saline ????????data from the same horse probably explains why lameness was 
significant using the LL, but not the AAEP score.  
Inertial sensor-based systems e.g. LL, showed repeatability in a straight line 
as used in this thesis and are comparable with gait analyses by video recording 
(Keegan et al., 2004; Keegan et al., 2011). It has also been proposed that intra- 
and inter-rater variability may bias and limit the usefulness of subjective gait 
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analyses scales such as the AAEP score (Keegan et al., 1998; Arkell et al., 2006; 
Hewetson et al., 2006). In Paper IV, LL was shown to be a more sensitive 
method to evaluate lameness than the AAEP scale. Paper IV also demonstrated 
between-animal MHH variation after LPS-challenge followed by saline injection 
(Figure 18). Incomplete ia injection might have contributed to the between-
horse variation in response to the LPS-challenge and the dexa-methasone 
treatment between the horses, despite care being taken when injections were 
performed. Aspiration of synovial fluid followed by injection performed 
without resistance was used as confirmation of correct needle placement within 
the joint cavity. Lack of an objective confirmation method (e.g. 
ultrasonography) of needle placement is a weakness that should be considered 
in interpretation of the results. However, between-animal variation in lameness 
induced by comparable doses of LPS administered ia has been reported 
(Ishihara et al., 2005; Santos et al., 2009; van Loon et al., 2013).   
Joint circumference, skin temperature and rectal temperature  
The LPS-challenge increased the JC response (p=0.03) and ST response (p=0.03) 
compared with the contralateral non-challenged joint (Figure 19). The increase 
in ???????? for the ST and JC response was larger after saline injection than 
after dexamethasone injection for all doses except for 0.01 mg. The difference 
between treatments was not significant (p=0.16 and 0.06 for ST and JC 
response, respectively). There was no difference in RT between the two 
treatments. No signs of septic arthritis were observed during the study or in the 
following days. In Paper IV, none of the variables ST, JC or AAEP score 
decreased significantly during treatment with LPS + dexamethasone compared 
with LPS + saline. However, in the work presented in the present thesis the 
????????  parameter decreased for all three variables after ia dexamethasone 
(Figure 19). Despite that the differences between the two study protocols not 
were statistic significant, Figure 19 show a potential decrease in AAEP score, ST 
and JC after treatment with dexamethasone compared with treatment with 
saline. A likely explanation for the non-significant results is the low 
dexamethasone exposure following the lowest doses used combined with a 
small study population consisting of 6 horses. Consistent with Paper IV, 
significant lameness reduction but no significant decrease in JC after ia 
injections of glucocorticoids has been shown in horses (Kay et al., 2008). 
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Figure 19. Boxplot showing the area under the curve from baseline to last observation ( ????????) 
for the clinical responses local skin temperature, joint circumference, AAEP lameness score and 
rectal temperature after lipopolysaccharide (LPS)-challenge treated with saline (NaCl) or 
dexamethasone (Dex) intraarticularly. In the upper plots, the negative control refers to the 
contralateral non-challenged joint. The box borders represent the first and the third quartile. The 
thick line represents the median and the whiskers represent 1.5 times the inter quartile range. 
Open circles represent observations not included within whisker range. *indicates statistically 
significant difference (p<0.05) between negative control and LPS + saline treatment. 
Lameness response-time course 
The observed LL response score data from all horses are shown in figure 18. 
The LPS-challenge + ia saline induced a difference in MHH in all horses 
compared with baseline. Median (range) MHH was 96 mm (12-196). The 
maximum MHH was observed within 8 hours. The MHH score then returned to 
baseline within 24 hours after LPS-challenge in five horses and within 32 hours 
in one horse. For one horse MHH score indicated lameness in the contralateral 
forelimb between hours 24-52 after LPS-challenge + 0.3 mg dexamethasone. In 
that horse, the AAEP-score indicated lameness from hour 48 to 72. 
Pharmacodynamic model  
A PD model was fitted to experimental lameness response data from five 
horses. It was not possible to fit the model to data from the horse treated with 
the lowest dose (0.01 mg). The observed and fitted lameness scores from two 
Neg. Control LPS+NaCl LPS+Dex
2100
2200
2300
2400
Sk
in
 T
em
pe
ra
tu
re
Jo
in
t C
ir
cu
m
fe
ra
nc
e
2300
2400
2500
2600
2700
Neg. Control LPS+NaCl LPS+Dex
LPS+NaCl LPS+Dex
0
20
40
60
80
A
A
E
P 
Sc
or
e
2830
2840
2850
2860
2870
LPS+NaCl LPS+Dex
R
ek
ta
l T
em
pe
ra
tu
re
⃰
⃰
⃰
⃰
55 
horses are shown in Figure 20 and the simulated equilibrium steady state 
dexamethasone-lameness response relationship for two horses is shown in 
Figure 21. The model parameters were in median (range) 0.32 per hour (0.18-
0.35), 3.3 mm (3.1-4.8) and 16 (8.2-43.6) for the kLPS, ALPS and γ-parameter, 
respectively. The corresponding value for the PD model parameter Ainhib 0.06 
per concentration (0.0004-0.19) and the calculated concentration at which 
lameness is reduced by 50 % was 15 ng∙mL-1 (5-2000). The variation in the 
amplitude parameter was lower compared to the 14-fold between-animal 
variation in MHH data. The decreased between-animal variation in amplitude 
was a result of the additional γ-parameter. The use of this parameter as an 
exponent in the LPS-challenge function was necessary to capture the rapid onset 
and peak observation of the challenge in the sparse experimental data. 
 
Figure 20. Observed (symbols) and model-predicted (lines) differences in minimum head position 
scored by the lameness locator system in two horses challenged with 2 ng lipopolysaccharides 
(LPS) in the carpal joint at hour 0. At hour 2, either saline (filled circles, solid lines) or 
dexamethasone (empty circles, dashed lines) was injected (DEX) in the LPS-challenged joint at a 
dose of 0.3 mg (left plot) and 3 mg (right plot).  
Fitting a PD model to experimental LL response data provided input data to 
demonstrate the equilibrium dexamethasone synovial fluid concentration-
response relationship (Figure 21). The PD model captured the onset, intensity 
and duration of both LPS-challenge and response to dexamethasone (Figure 
20). Concentration values at 50 % suppression of the lameness response after 
dexamethasone treatment were derived. There was a 400-fold variation in 
derived concentrations at 50 % suppression of the lameness response, because 
the horse treated with 0.3 mg dexamethasone was an outlier. The high 
sensitivity to the LPS-challenge in combination with the relatively low dose 
dexamethasone resulted in high LL-response score after treatment with 
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dexamethasone in this horse compared with the other horses (Figure 20). Since 
the PD model only included one PD parameter (Ainhib) this resulted in low 
parameter value and high derived concentration values for 50 % suppression of 
lameness response. If it would have been possible, the use of a more complex 
PD model (e.g. Imax-model) might have adjusted for this. Then the efficacy 
parameter would have estimated the low intensity of response in this horse and 
the potency value probably lower. However, due to the sparse experimental 
data was it not possible to use those PD-models to estimate parameters with 
precision and low parameter correlation.  
 
Figure 21. Simulated equilibrium dexamethasone synovial fluid concentration-lameness response 
relationship. The plots are based on pharmacodynamic lameness response data from paper IV. 
One horse where lameness was supressed with 50 % at lower dexamethasone synovial fluid 
concentration (upper plots A) and one horse where lameness was supressed with 50 % at higher 
dexamethasone synovial fluid concentration (lower plots, B). Arrows indicate the estimated 
concentration at where lameness was supressed with 50 %. The linear plots (left column) show 
that an equivalent change in concentration produced a larger change in response at lower 
concentrations compared with the higher concentrations. The semi-logarithmic plots (right 
column) highlight the concentration range for the largest change in response. 
However, when PD data from the horse treated with 0.3 mg dexamethasone 
were excluded, the concentration at which lameness was supressed by 50 % 
showed a 9-fold variation (5-45 ng∙mL-1) between the four remaining horses. 
The 9-fold variation is consistent with previously reported variation in potency 
values within a study population (Toutain et al., 2001) The range 5-45 ng∙mL-1 
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is also consistent with the tentative potency value for IL-1β response (19 
ng∙mL-1) in synovial fluid in this thesis. The LL-response to LPS-challenge 
followed by saline treatment returned to baseline within 32 hours in all horses. 
Therefore, a maximum of seven observations were made after each treatment. 
In addition, LPS-challenge + dexamethasone treatment data indicate full 
inhibition of LL response in five horses. Consequently, it was not possible to fit 
a more extended PD model (e.g. sigmoid Imax-model) to the data-set and obtain 
model- estimated parameters. The fit of a less complex model to data in order 
to mimic the LL-response-time course was successful in five horses but with 
relatively low precision of the Ainhib-parameter. Hence, the parameter should be 
interpreted with caution and the tentative quantitative information given in 
Paper IV should primarily be used as input to future experiments. The 
dexamethasone synovial fluid concentration at which lameness is reduced by 
50 % can also be used in anti-doping methodology for control of therapeutic 
substances. 
Interestingly enough, the horse treated with 0.03 mg dexamethasone 
became lame on the opposite non-challenged/non-treated leg after treatment 
with dexamethasone (Figure 22). Neither LL response score nor AAEP response 
score indicated lameness for this horse during base-line. However, it was de-
noted “asymmetrical” in trot. One possible explanation might be that the horse 
had similar pain in both front limbs. The treatment with dexamethasone then 
produced an anti-inflammatory response that decreased lameness in the treated 
joint and lameness on the contralateral leg became detectable. 
 
 
 
 
 
 
Figure 22. Observed difference in minimum head position over time in one horse treated with 
lipopolysaccharides (LPS) + saline (filled circles) and LPS + 0.3 mg dexamethasone (empty 
circles) intraarticularly. Negative values indicate lameness on the contralateral leg. 
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6 General Discussion 
    
6.1 Cortisol response and clinical response in a biomarker 
perspective 
6.1.1 General biomarker considerations 
Biomarkers can be used for instance to predict the clinical outcome of drug 
treatment. One classification of biomarkers used in quantitative pharmacology 
aims at placing the biomarker somewhere on the causal path between 
phenotype and response (Peck et al., 2003; Danhof et al., 2005; Rolan et al., 
2007). Danhof et al. (2005) presented a classification of biomarkers with seven 
different categories namely phenotype/genotype, drug concentration, target 
occupancy, target activation, physiological response, patho-physiological 
response and clinical response (which are clinical endpoints rather than 
biomarkers per se). Using this classification and quantitative information on 
the biomarkers might increase the precision in prediction between species and 
from experimental to clinical studies.  
6.1.2 Cortisol from a biomarker perspective 
It is unlikely that cortisol response can be considered on the causal path 
between dexamethasone administration and the anti-inflammatory response. 
However, if quantitative PD data on cortisol response are consistent with 
biomarkers on the causal pathway to anti-inflammatory response, cortisol 
response could be an option for screening other glucocorticoid substances. The 
quantitative information could then be used in the anti-doping control 
methodology of therapeutic substances in racing and equestrian sports. 
Unfortunately, the data presented here did not include any suitable biomarker 
in the healthy horse. During the experimental work in Paper II, samples were 
collected to evaluate gene (mRNA) expression and quantification in plasma of 
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e.g. IL-1β, IL-10 and Annexin A1. Unfortunately, the quality and amount of 
mRNA in the samples were insufficient for further analyses. Moreover it was 
not possible to quantify cytokines or Annexin A1 due to insufficient sensitivity 
of the analytical assays (data not shown). Nevertheless, cortisol response might 
be a useful biomarker for purposes other than anti-inflammatory response 
screening. In Papers I and II a clear plasma dexamethasone concentration-
cortisol response relationship was shown. It is reasonable to believe that intra 
cellular concentration of dexamethasone is more important for the response 
since the glucocorticoid receptor are mainly located within the cell (Baxter & 
Tomkins, 1971; Levinson et al., 1972). It is also reasonable to believe that 
there is equilibrium in steady state between concentration in plasma and intra-
cellular concentration since no active transport of dexamethasone over the cell 
membrane has been reported. Consequently, dexamethasone plasma exposure 
profiles might be relevant for use as surrogate concentrations in PD analyses of 
the response to dexamethasone. The median potency-value for cortisol 
response based on the data presented in this thesis is 39 pg∙mL-1. In 
comparison, the potency-values for IL-1β response and lameness response 
presented in Papers III and IV were approximately 1000-fold larger. This 
indicates that cortisol response is a sensitive biomarker of systemic exposure to 
dexamethasone in horses. This is consistent with reports that cortisol response 
in humans is more sensitive to glucocorticoid plasma exposure than 
lymphocyte response and neutrophil response (Mager et al., 2003; Stark et al., 
2006).  
6.1.3 Example on a clinical application of quantitative information 
The quantitative model-based analysis of cortisol response was also used to 
evaluate and suggest improvement in the predictability of one dexamethasone 
suppression test protocol originally presented by Dybdal et al. (1994). The 
results presented in Paper II (Figure 15) suggest that a protocol based on a 
single sample might be misleading when interpreting the test result. Hence, 
additional samples are recommended to increase the predictability of the test.  
6.1.4 Lipopolysaccharide-challenge model from a biomarker perspective 
Intraarticular LPS injection in challenge tests has been widely used in horses. In 
doses up to 2.5 ng the LPS-challenge induced local inflammation and produced 
e.g. lameness response, JC response, ST response and synovial fluid cytokine 
response (Palmer & Bertone, 1994; Easter et al., 2000; Campebell et al., 2004; 
de Grauw et al., 2009; van Loon et al., 2010; Ross et al., 2012). At this LPS 
dose level, the horses continued to bear weight on the treated leg and no 
clinical relevant signs on systemic variables (e.g. fever) have been reported. 
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The lameness response duration is 24-48 hours. LPS doses at 25 ng or higher 
increased the intensity and duration of the LPS-challenge and at those dose-
levels the horses are unwilling to bear weight on the LPS-challenged leg, while 
the challenge also affects systemic variables, e.g. increased rectal temperature 
and heart rate (Hawkins et al., 1993; Palmer & Bertone, 1994; Lindegaard et 
al., 2010). 
In Paper IV, there was no difference in rectal temperature between the two 
treatment protocols or between base-line and LPS + saline treatment. All horses 
maintained their appetite throughout the time range studied. The horses were 
willing to be led by hand (both in walk and in trot). The IL-1β response and 
lameness response during treatment with LPS + saline was characterised by 
rapid onset, short duration and relatively rapid return to baseline. Release of 
another pro inflammatory cytokine, tumour necrosis factor alpha, induced by 
LPS administered ia in horses or iv in other species show similar time courses, 
but with shorter duration (Campebell et al., 2004; Wang et al., 2007; 
Gabrielsson et al., 2015). However, the results presented in this thesis are 
consistent with reported lameness duration induced by comparable LPS doses 
administered ia to horses (Palmer & Bertone, 1994; Easter et al., 2000; Santos 
et al., 2009). During treatment with LPS + dexamethasone IL-1β response and 
lameness response were lower than treatment with LPS + saline. 
 The challenge test in this thesis was designed to mimic a clinical situation. 
Therefore, the LPS-challenge was administered two hours before the 
dexamethasone or saline treatment instead of injecting the drug before the 
challenge which is another challenge test design (Salomone et al., 1998; 
Primiano et al., 2016). The modelling of biomarker response data after LPS-
challenge was performed using a model with a time-dependent stimulator 
function acting on the input rate of biomarker response. This approach has 
recently been reviewed (Gabrielsson et al., 2015). An alternative option would 
have been a model with discontinuous stimulatory functions allowing 
biomarker formation to take place only during a defined period (Gozzi et al., 
1999; Chakraborty et al., 2005; Wyska, 2010; Sukumaran et al., 2012). 
However, the use of a continuous stimulatory function might mimic the 
physiological response more adequately and probably allow a more 
biologically relevant description of the biomarker-time course. The model 
accurately mimicked experimental data (Figures 17 and 20). Experimental data 
on the biomarker response-time courses and the unaffected biomarker baseline-
time course were modelled simultaneously in Papers II, III and IV (the data-set 
in Paper I did not include any control data). Simultaneous fitting of the model 
to data from all dose-levels allowed the model to use all available information 
in the data-set during estimation of the model parameters and increased the 
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parameter precision (Draper & Smith, 1998; Gabrielsson & Weiner, 2016). In 
light of the sparse data-set and the different doses used in Papers III and IV, the 
model-predicted biomarker response-time courses and the parameter estimates 
seem reasonable. The consistency across the studies using two different models 
suggests that the concentration range where lameness is supressed by 50 % lies 
somewhere within the true potency range of the studied population, despite the 
low parameter precision.  
6.2 Dexamethasone in a medication perspective 
6.2.1 Response to intraarticular glucocorticoid injections 
In Paper IV, ia dexamethasone was shown to reduce lameness response 
induced by LPS-challenge of the equine joint at doses lower than the approved 
dosses (Medical Products Agency, 2015). It has been clearly shown in both ex-
perimental and clinical studies that glucocorticoid therapy at approved doses or 
doses commonly used by clinicians reduces clinical signs of joint disease 
(Trussel, 1965; Van Pelt & Riley, 1967; Houdeshell, 1969, 1970; Van Pelt et 
al., 1970; Van Pelt et al., 1971; Vernimb et al., 1977; Salles-Gomes et al., 
2003; Kristiansen & Kold, 2007; Labens et al., 2007; Kay et al., 2008; 
Brommer et al., 2012; de Grauw et al., 2016; Knych et al., 2017b). In those 
studies, no synovial fluid glucocorticoid concentrations were quantitatively 
related to the biomarker response and few doses were evaluated. The response 
to ia treatment with dexamethasone has been explored in the dose range 6-12 
mg per joint (Salles-Gomes et al., 2003; Brommer et al., 2012). Those studies 
did not include any control treatment (e.g. saline).  
6.2.2 Glucocorticoid dosing from a safety perspective 
The efficacy of dexamethasone at the dose levels used in this thesis is 
important. It has been proposed that glucocorticoid exposure has a detrimental 
effect on equine cartilage. Under non-inflammatory conditions such studies 
have comprised both in vivo and in vitro experiments across various 
biomarkers for cartilage turnover and including various glucocorticoids 
(Chunekamrai et al., 1989; Trotter et al., 1991; Saari et al., 1992; Todhunter et 
al., 1998; Robion et al., 2001; Murray et al., 2002; Celeste et al., 2005). As 
biomarkers for unwanted effects on cartilage, proteoglycan synthesis, collagen 
syntheses and glycosaminoglycan synthesis have been used, among others. The 
potentially detrimental effects appear to increase with increased glucocorticoid 
exposure (Jolly et al., 1995; Todhunter et al., 1996; Murphy et al., 2000; 
Fubini et al., 2001; Frean et al., 2002; Richardson & Dodge, 2003; Doyle et 
al., 2005). Inflammatory conditions are also potentially detrimental for the 
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equine joint and glucocorticoid exposure appears to partly reverse these effects 
(Frisbie et al., 1997; MacLeod et al., 1998; Todhunter et al., 1998; Bolt et al., 
2008). One proposed explanation is that matrix breakdown during 
inflammatory processes in the joint due to increased enzymatic activity, for 
instance by cyclooxygenases, matrix metalloproteinases and aggrecanase, 
which are inhibited by glucocorticoids (Tung et al., 2002; Busschers et al., 
2010; Garvican et al., 2010).  
Combined with the demonstrated dose-response relationship the quan-
titative input is beneficial. Based on the model parameters the dexamethasone 
synovial fluid concentration-response relationship (Rss) was simulated in this 
thesis. The simulation results indicated that a small change in concentration 
within the concentration range around the potency value produced a relatively 
large change in response (Figure 21). At synovial fluid concentrations 
obviously higher than the potency value, a large change in concentration 
produced a relatively small change in response.  
6.2.3 Lower doses from a safety perspective 
Lower doses might increase the number of injections needed to maintain drug 
exposure over time. Moreover, there are case reports describing septic arthritis 
after ia injections in horses (Lapointe et al., 1992). During the experimental 
work in this thesis, a total of 156 joint punctures were performed.  No signs of 
septic arthritis were detected during the experiment or in the following days. 
This result suggests that the risk of infection is low when aseptic injection 
techniques are used. This is also supported by a recent report suggesting that 
infection is uncommon following joint injections (Steel et al., 2013). 
Nevertheless, septic arthritis is a severe condition and the risk should not be 
neglected. The use of a local route of administration without puncture of the 
joint would eliminate the risk of septic arthritis. Iontophoresis can transport 
dexamethasone across the skin and in theory deliver dexamethasone into 
synovial fluid. The technique has shown to be effective compared with placebo 
for knee pain in humans (Li et al., 1996; Paturi et al., 2010). Unfortunately the 
observed maximum dexamethasone concentration after iontophoresis is lower 
than 2.3 ng∙mL-1 synovial fluid (Kaneps et al., 2002). This can be compared to 
the concentration range 5-45 ng∙mL-1 (outlier data not included) at 50 % 
suppression of LL response presented in this thesis. For now, joint puncture 
appears to be the only option for treating osteoarthritis locally with 
dexamethasone.  
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6.2.4 Future perspectives and animal welfare considerations 
The use of a sustained release formulation has the potential to reduce both the 
free glucocorticoid concentration in synovial fluid and the number of 
injections. The terminal half- life in synovial fluid is 3 days (2-7), 0.8 days 
(0.6-4) and 0.5 days after ia administration of methylprednisolone acetate, 
triamcinolone acetate and isoflupredone acetate, respectively (Knych et al., 
2013; Knych et al., 2014; Knych et al., 2016). The initial and terminal synovial 
fluid half-lives after ia administration of betamethasone phosphate/acetate is 
0.5 and 8 days respectively (Knych et al., 2017a). A treatment protocol with 
documented response (effect) that also minimises the risk of detrimental effects 
in the joint and lowers the risk for septic arthritis improve animal welfare. Data 
from exposure studies (e.g. Knytch et al., 2014) combined with future studies 
of the glucocorticoid synovial fluid concentration-response relationship are 
also needed to estimate the duration of response after ia injection of other 
glucocorticoid substances. This quantitative information would improve 
existing treatment protocols and anti-doping control of therapeutic substances 
in equine athletes, which is important for animal welfare.   
6.3 Dexamethasone in an anti-doping perspective 
To ensure the animal welfare of equine athletes, they must be given accurate 
medical treatment if they suffer disease or injury. To protect the integrity of the 
sport and the animal welfare, horses are not allowed to participate in com-
petition during medical treatment. To minimise the risk of drug-traces at 
irrelevant concentrations after legitimate administrations to horses being 
detected in doping controls and falsely lead to doping accusations, DT, WT and 
SL are used by the regulatory authorities and practising veterinarians  (Wong & 
Wan, 2014).  
6.3.1 Screening Limits 
Toutain  & Lassourd (2002) introduced a model to decide SL based on plasma 
concentrations after administration of a dose of a drug that is assumed to 
produce therapeutic plasma concentrations. In Paper I, the exposure of 
dexamethasone in plasma an urine after injection of 0.03 mg∙kg-1 dexa-
methasone-21-isonicotinate im were described. This dose was decided based 
on an assumed horse weight of 500 kg and the approved volume 15 ml 
Vorenvet vet. (1 mg∙mL-1) as described in the summary of product charac-
teristics (Medical Products Agency, 2010). Hence, the observed plasma 
concentration was assumed relevant for calculation of irrelevant plasma 
concentration of dexamethasone. The observed maximum dexamethasone 
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plasma concentration ranged from 0.5 ng∙mL-1 to 0.8 ng∙mL-1. A safety factor 
(SF) of 500 as proposed by Toutain & Lassourd (2002) applied on plasma data 
suggests the SL 1 pg∙mL-1 plasma. Unfortunately, there are no PD plasma data 
available relating the anti-inflammatory response to plasma concentration of 
dexamethasone. Compared with the IC50-range for cortisol response (6-132 
pg∙mL-1 plasma) the irrelevant plasma concentration appeared appropriate. 
Applying a SF of 500 to the lowest proposed synovial fluid concentration 
reducing the lameness response by 50 % reported in Paper IV (5 ng∙mL-1) 
gives a value of 10 pg∙mL-1. This is not a proposed irrelevant concentration or 
SL. More quantitative data are needed to establish a therapeutic concentration 
based on scientific data. However, it confirms the need for low SL for 
dexamethasone as proposed in this thesis. It is possible to use a lower SF if 
there is quantitative PK and PD information about the drug (Toutain & 
Lassourd, 2002). Since cortisol response cannot be assumed to be on the causal 
pathway between dexamethasone exposure and anti-inflammatory response 
future quantitative studies on other biomarkers are warranted. Inadequate 
quantitative PD information increases uncertainty and consequently the size of 
the SF needed in calculations of IPC. Until scientific data support the use of a 
smaller SF than used in this thesis for calculation of IPC, a low SL as proposed in 
this thesis is recommended to ensure animal welfare, clean sport and fair 
competition.  
Urine is the most commonly used matrix in anti-doping control (Toutain, 
2010b). However, in terms of control of legal therapeutic substances, urine is 
not as suitable as plasma. The urine concentration is often decided by the 
plasma concentration and plasma concentration is most often a better surrogate 
marker for drug concentration at the target site. In addition, for some drugs 
renal clearance is low and the main route of elimination is via the feces. 
However, drug concentrations are often higher in urine and are also affected 
by, for instance, urine volume (e.g. during dehydration) so the relation between 
concentrations in plasma and in urine might be imprecise. Consequently, there 
is a risk of detecting traces of legitimate medication in urine when plasma 
concentrations might be considered without relevant effect. Urine dexa-
methasone data displayed higher inter- and intra-individual variation than 
plasma dexamethasone data in this thesis. This variation most probably reflects 
the horses’ states of hydration since urine volume varies both over time and 
between individuals. In this thesis, this variation was not corrected for, since 
the aim of sampling urine was to obtain data for the control of therapeutic 
substances.  Inspection of the dexamethasone urine and plasma concentration 
plot obtained here (Fig. 2) suggests a correlation between plasma and urine 
concentrations in the population studied, with a urine/plasma ratio in the 
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terminal phase of approximately 10. Applying this ratio would suggest a urine 
SL of 10 pg∙mL-1 based on a plasma SL of 1 pg∙mL-1 and the model proposed by 
Toutain & Lassourd (2202). Unfortunately, there is no international SL 
published for dexamethasone in plasma. The proposed SL of 1 pg∙mL-1 can be 
compared with the threshold of 5 pg∙mL-1 used by the Association of Racing 
Commissioners International (ARCI) to estimate WT after administration of DSP 
(ARCI, 2016). In urine, the SL of 10 pg∙mL-1 presented in this thesis can be 
compared with the published international SL of 200 pg∙mL-1 (IFHA, 2017b) 
6.3.2 Detection times and withdrawal times 
After im administration of dexamethasone-21-isonictinate, dexamethasone was 
quantifiable in plasma (LLOQ 25 pg∙mL-1) for 13 days and in urine (LLOQ 150 
pg∙mL-1) for 14 days. This is equivalent with the DT proposed by EHSLC, which 
is based on the SL used by EHSLC for dexamethasone (EHSLC, 2015). To allow 
the dexamethasone plasma concentration to drop below 5 pg∙mL-1 in all horses, 
this time would be extended by 6 days using the terminal half-life for 
dexamethasone in plasma presented in this thesis (Table 3). 
Paper I used six horses with high between-animal variation in elimination 
rate. The DT should therefore be doubled to produce a WT (Toutain, 2010a). It 
is important to mention that the figures presented in this thesis have not been 
approved by any regulatory organisations or any other organisation associated 
with racing or equestrian sports (e.g. EHSLC). A WT is commonly a re-
commendation chosen by the treating veterinarian after all circumstances are 
accounted for to minimise the risk of positive findings in doping-control on 
race day (EHSLC, 2012). In the Nordic countries, recommendations similar to 
WT are given by the racing authorities. In Paper II DSP was administered iv as a 
bolus + constant rate infusion regimen in doses different from the approved 
doses (Medical Products Agency, 2015). In paper III, DSP was administered ia. 
Only the 3 mg dose is consistent with an approved dose (Medical Products 
Agency, 2015). Therefore, the dexamethasone data presented cannot be used to 
determine DT. The EHSLC reports the DT 5 days after iv administration of DSP 
(EHSLC, 2015). There is no DT information available after ia administration of 
DSP. 
6.3.3 Anti-doping control after intraarticular administration 
The dexamethasone plasma concentrations were 200-fold to 10000-fold lower 
than the dexamethasone synovial fluid concentrations (Figure 6). At obser-
vations made longer after the time of injection the difference between plasma 
and synovial fluid concentrations were smaller compared with observations 
closer to the time of injection. The relatively large and variable range of 
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concentration difference indicates low success rate in extrapolating concen-
trations from synovial fluid to plasma and vice versa. Dexamethasone plasma 
concentrations also fell below the LLOQ of the analytical method before 
synovial fluid concentrations did. Detection of dexamethasone concentrations 
in plasma or urine after ia injection of DSP suggests that the horse was treated 
relatively recently. However, this thesis suggests that neither urine nor plasma 
is a good indicator to predict dexamethasone synovial fluid concentration. This 
was previously discussed by Toutain (2010b) and similar conclusions have 
been reached after ia injection of other glucocorticoids (Knych et al., 2013; 
Knych et al., 2014; Knych et al., 2016; Knych et al., 2017a). To ensure animal 
welfare and protect the integrity of the sport methods other than taking anti-
doping control samples during competition could be used. A stand-down 
period after ia glucocorticoid injection combined with compulsory medication 
records is one alternative approach to the problem. This should be combined 
with out of competition testing that enables comparison with the medication 
record and the laboratory report.  
6.3.4 Can control of therapeutic substances be improved? 
One future complement to the use of drug concentration in anti-doping control 
is the use of biomarker quantification. A biomarker on the causal pathway 
between drug exposure and response has the potential to increase reliability in 
predicting the intensity of the drug response compared with a single-time point 
observation such as drug plasma or urine concentration. This requires further 
studies on biomarker baseline, drug concentration-biomarker response relation-
ship and establishment of biomarker thresholds for negative tests. The use of 
biomarkers would also increase the possible time for detection in control of 
substances with short plasma/urine half-life and long duration of response. The 
use of an enlarged anti-doping control methodology would increase under-
standing as well as trust in control of therapeutic substances among both the 
public and practitioners in racing and equestrian sport, which improve animal 
welfare and protect the integrity of the sport. 
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7 Conclusions 
The overall aim of this thesis was to study dexamethasone exposure and 
response in Standardbreds by means of quantitative methods. The work 
described in the thesis comprises studies on horses treated with dexamethasone 
intramuscularly, intravenously and intraarticularly. The dexamethasone conc-
entration in plasma and synovial fluid was found to be related to the response. 
The dexamethasone urine concentration appeared to be related to the plasma 
concentration. The results obtained allow the following conclusions to be 
drawn on the dexamethasone concentration-response relationship.  
 
? Dexamethasone concentration-time courses in plasma and synovial fluid 
was quantified after intramuscular, intravenous and intraarticular admini-
stration. The dexamethasone concentration-time course in urine was similar 
in shape to that in plasma but concentrations were higher at equivalent time 
points. The disposition in Standardbreds is consistent with Thoroughbreds. 
? Dexamethasone is potent and efficacious. A dexamethasone concentration-
response relationship was shown. The clinical endpoint lameness was 
suppressed at doses lower than approved doses.  
? Cortisol baseline and cortisol response were quantified and the results were 
used to suggest improvement of a diagnostic test. 
? IL-1β and lameness responses to dexamethasone treatment in an LPS-
challenged joint were quantified. The relatively large difference in potency 
compared to cortisol response suggests that cortisol is not a suitable 
biomarker for the anti-inflammatory response to dexamethasone.  
? A low screening limit for dexamethasone was indicated. Information on 
dexamethasone exposure was provided. An optional strategy in anti-doping 
control of therapeutic medication after intraarticular administration of dexa-
methasone was proposed. Plasma and urine were found not to be good 
indicators of synovial fluid dexamethasone concentration. 
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8 Future perspectives 
New knowledge commonly produces new questions. This thesis provided 
information of dexamethasone that can be used in future research, dosing 
recommendations and anti-doping methodology. Quantitative information on 
other glucocorticoids used in horses would have the potential to increase 
animal welfare by means of optimised dosing regimens and improved anti-
doping control.  
Future identification of a biomarker that can be used to investigate other 
glucocorticoids with respect to their PD properties is warranted. The protein 
Annexin A1 might fit the criteria. In this thesis, unsuccessful attempts were 
made to quantify Annexin A1 in plasma. Future research is recommended to 
focus on validation of a quantitative method that instead uses the white blood 
cells where the protein is synthesised and stored.    
Reliable PK and PD information provides a base for a dosage regimen. The 
screening of glucocorticoid substances by means of a biomarker strategy would 
provide data that indicate if the doses currently used are adequate or whether 
adjustments can be made.  
The PK and PD properties of glucocorticoids used in sustained release 
formulations (e.g. triamcinolone acetate, betamethasone acetate and methyl-
prednisolone acetate) should be characterised in the inflamed joint. The novel 
finding in this thesis that dexamethasone decrease lameness at doses lower than 
the approved doses (Medical Products Agency, 2015), combined with that 
glucocorticoids have potentially detrimental impact on cartilage turnover in a 
dose-dependent manner, indicate that lower doses would be safer and improve 
animal welfare. 
Implementation of a biomarker strategy might be viable a complement to 
drug concentrations in anti-doping control in racing and equestrian sports.  
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9 Populärvetenskaplig sammanfattning 
Dexametason är en substans inom en grupp anti-inflammatoriska läkemedel 
som i dagligt tal kallas för kortison. Kortison är vanligt för behandling av både 
tävlingshästar och sällskapshästar mot inflammation i leder, senor, muskler 
m.m. Läkemedlen kan ges till hästen på flera sätt, till exempel via munnen eller 
injiceras i blodet, i muskeln eller direkt i en led. Kortisonpreparat är effektiva 
läkemedel som gör stor nytta men tyvärr är de också förknippade med flera 
biverkningar, framförallt vid höga doser eller längre tids medicinering. 
För att upprätthålla en god djurvälfärd är det viktigt att hästar får god vård 
när de är sjuka eller skadade. Det är också viktigt att hästar inte tävlar när de är 
påverkade av läkemedel, både av djurvälfärdsskäl samt för dopningsfri sport. 
Olika hästsportorganisationer världen över har olika regelverk som reglerar 
medicinering av djur inför tävling. I Sverige regleras det även i Jordbruks-
verkets föreskrifter. De senaste årtiondena har analysmetoderna på anti-
dopningslaboratorierna blivit mer känsliga och läkemedel kan detekteras vid så 
pass låga koncentrationer i blod eller urin att läkemedlet inte längre kan anses 
ha någon effekt. Läkemedel kan till och med påvisas i prov från en obehandlad 
häst som placerats i en box där en behandlad häst tidigare stått om inte boxen 
inte gjorts rent ordentligt. För att hantera den problematiken har häst-sportens 
organisationer infört så kallade rapporteringsnivåer (screening limits, SL). En 
SL är en koncentration i blod eller urin vid vilken läkemedlet inte har någon 
effekt. Vetenskaplig dokumentation ligger till grund för vilken koncentration 
som bestäms. Om läkemedelskoncentrationen i ett prov ligger under en 
angiven SL rapporteras det som ett negativt prov. Ytterligare en åtgärd för att 
undvika dopningsutredningar vid regelrätt utförd medicinering är införande av 
detektionstider, detection times (DT) som är ett mått på hur lång tid det tar efter 
behandling med ett läkemedel till dess att koncentrationen är lägre än dess 
respektive SL. Utanför Skandinavien och Finland är det därför vanligt att den 
behandlande veterinären lägger till en säkerhetsmarginal till en DT för att 
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erhålla en withdrawal time (WT), en tid som bör förflyta mellan sista medicin-
ering och start för att säkerställa att ett eventuellt dopningsprov blir negativt. I 
Skandinavien och Finland motsvaras WT närmast av de fastställda karens-
tiderna.  
I arbetet inför den här avhandlingen har kortisonsubstansen dexametason 
givits till hästar i syfte att studera hur den tas upp, fördelas och försvinner från 
hästen. Koncentrationen dexametason har även relaterats till olika biomarkörer 
(ämnen som används som surrogat för att mäta läkemedelseffekten) och 
kliniska effekter för att kunna utvärdera behandlingsresultatet bland annat med 
så kallade kvantitativa metoder. Resultatet kan sedan användas i antidopnings-
arbetet, till exempel som underlag för att beräkna SL eller för att utvärdera de 
doser som används idag.  
I studie I mättes dexametasonkoncentrationen i blod och urin efter en 
injektion i muskeln av ett långtidsverkande preparat. Läkemedlet är utformat 
för att bilda en depå i muskeln och långsamt distribueras ut i blodet för att få 
effekt under längre tid. Läkemedelskoncentrationerna i blodet följdes över tid 
och tiden det tar att minska koncentrationen i blodet med 50 % (halverings-
tiden) beräknades. Med hjälp av halveringstiden går det att beräkna hur lång tid 
det tar för koncentrationen i blodet att sjunka till en bestämd koncentration, till 
exempel en SL. Läkemedelskoncentrationen i blodet relaterades också till 
hämningen av det kroppsegna hormonet kortisol och koncentrationen som ger 
halva maximala effekten beräknades.  
Vattenlösligt dexametason injicerades direkt i blodet i studie II och i 
inflammerad led i studie III, varpå prover togs och läkemedelskoncentrationen 
i blod och ledvätska fastställdes. Läkemedelskoncentrationen i plasma eller 
ledvätska minskar med hälften inom loppet av några timmar, varför upprepade 
injektioner krävs för att få effekt om längre tids behandling är nödvändig. 
Därefter bestämdes ett antal parametrar som anger hur läkemedel tas upp, 
fördelas och försvinner ur kroppen genom så kallad farmakokinetisk (PK) 
modellering. Med hjälp av resultatet från PK-modelleringen gick det även att 
relatera läkemedels-koncentrationen till effekten, med hjälp av så kallad 
farmakodynamisk (PD) modellering. Resultater styrkte också resultatet från 
studie I. Det har tidigare föreslagits att det inte går att relatera till exempel 
plasmakoncentrationen av kortison (glukokortikoider) till effekt, vilket den här 
avhandlingen således har motbevisat. 
Det kroppsegna hormonet kortisol visades vara en känslig biomarkör för 
dexametason i blod. Att kortisolkoncentrationen i blodet sjunker efter 
behandling med kortison är väldokumenterat och används till exempel vid 
utredning och diagnostik av så kallad Cushings sjukdom. Användandet av 
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farmakologiska modeller möjliggjorde utvärdering av ett sådant testprotokoll 
med konkreta förslag på förbättringar som underlättar tolkningen av testsvaret.  
De två sista studierna undersökte effekten av dexametason efter att en mild 
inflammation skapats i leden med hjälp av så kallade lipopolysackarider. 
Hästarna behandlades sedan med dexametason eller koksalt (placebo) direkt i 
leden. Om inflammationen behandlades med koksaltlösning blev hästarna halta 
i upp till 32 timmar. Efter injektion med dexametason direkt i leden lindrades 
eller släcktes hältan vid doser lägre än de som är godkända för ledinjektion i 
Sverige.  
Resultaten i den här avhandlingen kan användas både som underlag för att 
beräkna DT och SL samt jämföras med (och i framtiden eventuellt revidera) 
etablerade behandlingsprotokoll för kortisontypen dexametason för att minska 
risken för biverkningar. För andra kortisontyper och för de som är långtids-
verkande behövs mer information om hur de omsätts i leden samt hur mycket 
som behöver finnas i leden för att få en god effekt. Fram till dess att den kun-
skapen finns är det på sin plats att vara restriktiv i doseringen av de kortison-
läkemedlen. Det finns sedan tidigare forskning som pekar på att kortison kan 
påverka ledbrosk negativt och högre doser kan potentiellt ge större negativa 
effekter. Ett behandlingsprotokoll med lägre doser skulle kunna leda till färre 
oönskade effekter vilket är önskvärt. Det är viktig information att ta reda på för 
att i framtiden eventuellt kunna revidera behandlingsprotokollen och säkra en 
trygg och effektiv behandling samt en pålitlig kontroll av tillåtna mediciner 
inom anti-dopningsarbetet, vilket är betydelsefullt för djurvälfärden. 
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